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CBAImm I 
I NTRODUOTION 
I. matorl!!:b note on ohollne.tex-.... ' 
Dale (21) aa .ax-17 as 1914 augg •• ted that an .nz,.... 
pHsent In the blood brought about the d •• tnotion of Ach. Loew1 
(51) deaonatrated 1n 1926 the exi.tan •• ot aD ODa,.. In extracts 
prepared t.om heart muacle whiCh inacttvated a chollne •• ter 
identtt1ed later .. Aoh. Bngelhart and. Laewi (29) In 1930 
explalned. the d.at~otlv •• etion ot t~. blood Ach bJ 8uggesting 
the exiatane. ot an e.tera.e wbich was compl.tolJ Inh1bited b7 
minute amount. ot phJaoatlgm1n.. About the s... time, the 
oODd! tlona tor the lnaot! vation ot .lob were founcl to be conatstent 
wi th the aotlon ot an •• terase. Plattner and Buttner (11) were 
the tirst to show in 19)0 that the en.,... i. present 1n near17 
all anSmal tissue.. Stedman (76) proposed 1n 19.32 the name 
cholinesteraso tor tho anzJme that h7dro1Jze. chollne eat.re. 
II. 11.$&911;108 "tv«uta tht \!O me. ot choMM!teEllt , owu I 
UDoez-tatntJ prevailed as to whether or Dot the h7dJtro-
1,.a1. ot Aoh waa oata17.ed b'1 a speclfio .n.,.... Stedman (76) 
••• umed that 1RaD7 aeN oontalna two enzJ1D •• , at lo.at one b.lng 
a lbE the other an ord1IU117 e.tera... GllmaD and Goodmen (37) 
flr.' apoke about apeolflc and non-speciflc ChE. In a review b7 
1 
2 
Augustineson (5), an ens.,.. which hydrolyzed only choline eaters 
ia defined as a specifio abE. Suoh an enzyme haa beeD proved to 
exist in animal organisms. !he physiologioal substrate 01' this 
speoif10 enz1me 1s Ach. 
The non-.pecif1c ebE 1s today def1ned as the enzJme which 
can hydrolyze other e.ters in add1tioG to ~olin. eatera, the 
latter being aplit at a higher rate. Proof haa been o1'tered that 
O .. t:e 
at least~suoh non·.pec1f10 CbE occurs 1n the antmal organiam. 
However, the phys10logical function of this type 01' ChE 18 obscure 
and the natural sUbatrate is not wel1~ known. 
Investigation of sensitivity to difterent 1nhibitors 01' 
enz,.es trom various sourc.s oapable of splitting Aeh led Mendel 
and Rudney (60) to propose a general classification 01' enzymes 01' 
this type. i'he term "true" or "spe01tic" CbE was reserved tor tke 
enzyme. of erythrocyte. and nervous tissues_ which aoted O8ly on 
choline eatera, ineludtng Ach, acetyl ~-methJlcholine (Xecholyl) 
but not bensoylohollne, and whioh were inhibited b,. high ooncentr-
ation of Aoh. '1"h1. enzyme hydrolyze. choline eaters at a rate 
inversely proportional to the length of the carbon ohain. Certain 
common eaters are split at rates which can be arranged 1n the 
following order: but7l'7l (propionyl <aoetylcholine. Bence the 
name aoetylcholinestera.e (AcChE) was also given to the "true" CbB 
On the other hand, the term "pseudo" or non-specific CbE 
included the enzymes fram serum, panoreas and other tissues whioh 
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hydrolyzed .loh, benzoylcholine and several non-choline eaters such 
as tributyrin, trlproplonin and methylbutyrate but not Heoholyl. 
'l'h1s enzyme exhibl ted maximum aoti vi ty in the presence of high 
concentration of Ach. The rat. ot hydrolysis by serum 0hE 
increase. with the length ot the acyl Chain in the follOwing order 
acetyl<propionyl<butyrylahollne, 1.e. in reverse order compared 
to the sequence ot rates exhibited by AcChE. Hence the name 
butyrylchollnesterase (BuChE) was also given to this enzyme. 
III. Pez.iologiaa1 significance ot AaChE: 
.loChE and its substrate Ach~hold an tmportant position 
in the physiology ot the nervoua syste., while the importance of 
BuChE is atill obscure. The properties ot Ach ex.-ined by Dale 
in 1914, who made the assumption that Ach is a synaptio neuro-
humor. In 1921, Loewi waa the first to prove the exiatanae of a 
humoral transmitter tor the parasy.mpathetic nervous system and 
later postulated the hypothsis that paraayapathetio nerv.s aot by 
liberating trom their terminals a chemical substan.e, asaumea to 
be identical with Aoh, and in this wa,. tranami t the nerve impulae 
to their ertector organa. On the basis ot the exiatanc. in the 
cella ot conducting tissues ot an enzyme with. relatively high 
atfinity to .leh .aehmanahon and his coworkers (1939-1941) 
hypotheai.ed t~t .loh baa a physiological role in O.N.S. Kinetics 
ot the aotivity ot .lcChE satisti.s the postulate that the electric 
al activit1 ot the nervous system is initiated by the chemical 
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action ot Ach at the aynapaea. 
Altogether Naohmanahon as reoently as in 1960 held to a 
"unitarian" hypothesis aocording to which ChE is a prerequisite 
ofaxonal conduct1on as well as synaptic and neurohumoral trans-
mission. Generally however the synaptic and neurohumoral role of 
CbE is more acceptable to most investigatores in this field. 
Synaptio role ot CbE at the neuromyal junotion and in the C.N.S. 
1s partioularly pertinent to the present researoh and will be 
theretore described at some length. 
1. Neuromyal junction. .~ 
Brown and Feldberg (12), Fatt and Katz ()O) and others 
presented complete evidenoe for the ohemical transmission at the 
end-plate region. ebE alstem is aaid to be an integral part of 
the meohanism responsible tor the development and propagation ot 
action potential. The looalization of the hldrolyzing enzlme has 
been demonstrated bl histochemioal meana and ita local influence 
on the transmission ot the impulse haa been elucidated by the us. 
ot specific ChE inhibitors. The enzyme action at the aeuromyal 
junction eN.M.J.) does not oocur at other points ot the nerve-
muacle slstem. 
The role of Acl;i. as a aynaptic transmitter and of CbB as 
the other component of the cholinergic transmission system haa 
been most studied at the N.M.J. It was suggested (o.c.) on the 
baail ot certain properties ot this synapse that its transmislion 
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system may have .1m1l.~ Impo~tance at othe~ sIte. such .s the 
C.N.S. A. will b. seen from the next sectlon. evidence Is today 
avaIlable indIcating that such may be the case. 
2. Cent~al ne~vou. sTstem. 
a. B~a1n 0hE and cent~al t~an.mls.1on: 
!he p~e ... ee of sueh transmission system 1n the C.N.S. 
is possIble It the componen~s ot this system a~e present in the 
brain. The components .~e the chemical transmitter (Ach), an 
en~e to synthesize the transmitter (chollne acetylase) and an 
enzyme to hydrolyze the transmi tte~ (loChE). 
1. Ach has been tound in the b~ain in a concentratIon 
which could be oo~related with tha activIty ot the C.N.S. Gene~al-
11 no other choline e.ters have been shown to be present In the 
braIn. 
11. Choline acetyla.e (31) has been found in the braIn 
and its p~esenoe could be co~elated to an extent with the presene 
ot Ach in the b~a1n. Ach and cholIne aoetylase have been found in 
high concent~atlon In the cerebellum and In the Htlcular 
fo~atlon. 
111. Both AoObE and BuChE have been found In the b~aln. 
AcChB predominates In the gray matter. It has now been establish-
ed that the ensJae in all nerve tIssues Is eIther exclusIvely or 
predOminantly speoltio tor Ach. The localIzation ot AcChE i. 
cos-related with that of Ach In the brain: both are found In high 
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concentration in the cerebellum and the reticular tor.matlan. 
The CbE act1vity 1s correlated with neurogenesis and ontogenic 
development ot brain !unction, 1ncluding ontogenic emergenoe or 
electrical actIvIt7 ot the cortex (32). S1m1lar correlat10n was 
made with regard to choline acetylase. 
b. 8Rinal cord: 
Evidence exist. which indicates that at least 80me ot the 
important synaps.s 1n the spinal oord such as the synapse between 
the collateral and the Renshaw cell are oholinergic. The Renshaw 
cella (72) are looated in the ventral~root of the sp1nal oord. 
Recurrent oollatera1s ot the motoneuron impinge on the Renshaw 
cells. It ha. been proposed by Eccle. et al (28) that the Renshaw 
cell is an interneuron which ean be tired b'y antidromic stim:u1atlo 
ion of the motor nerves and which is capable ot evoking a wave ot 
hyperpolarization in the motoneuron. The ph8~aoo1ogical charact-
erisatIon or the synapse between the recurrent col1aterals ot the 
motoneuron and the Renshaw cell Indicates that this is a oholin-
ergic synapse (27,28). Lengo et 81 (S8) inve.tigated ~. ettect. 
of physostigmine and dlhydro (j-el7thro1d1ne on the trequency ot 
spike activit7 ot the Renshaw cell. !hey tound that dlhJd:ro-
~-erythroid1ne decreased the frequency of the burs; of the cell 
during the first tive msec. D1hJdro.~-erythr01dine also attenuat-
ed the duratIon ot the Renshaw burst (Bccles,26). In agreement 
with Ecoles (27,28) Longo tound that physostigmine prolonged the 
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duration of the d1scha~ge of the Renshaw cell bu~st. However 
measur~ent8 ot the relationship between the time course ot the 
Benshaw cell burst and stimulus strength yielded data inconsistent 
with the hypothesis that the dutation of the burst is determined 
solely by the rate ot the hydrolysis ot Ach. The etfect of 
physostigmine in prolonging the Renshaw cell burst can be explain-
ed on the basis that, in the p~esence of a reduced concentration 
of effective esterase, the rate of hydrolysis o~ Ach would proceed 
at a slower ~ate and the concentration of Ach available for 
oombinations with effector reoeptors ·would. be increased. Ach 
would cause then membraIllt change per8isting beyond the time of 
its physioal presenoe. 
o. Other 8ites in the Central nervous system: 
Other sltes in the C.B.S. may be oholinergic as implied 
by certain pharmacological investigations. Karcamar and Long (49) 
have studied antagoniSM of the toxici t1 ot an anticholinesterase 
(TEPP) by atropin8 .ubstitutes, and sugg.sted that both TEPP 
toxicity and protection against TEPP are central in nature. !hey 
have found that the structural changes in the atropine substItutes 
that increaae the peripheral cholinolytic potency also lncrease 
the anti-TEPP action supplying therefore evid.ence for the hypo-
thesis that cholinergio transmission is involved in the central 
action of TEPP and in its antagonisM by atropine-like compounds. 
Other pharmaoologioal evidenoe tor chol1nergic transmiss-
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ion in the C.N.S. was also obtained. It was shown for instance 
hat "hemioholiniums" whioh are thought to blook the formation of 
Aoh by blocking the transfer of choline to the site of the reaot-
ion, posses a highly toxic action against respiration via a 
oentral meohanism, probably within the relay oentera tor respir-
ation ot the spinal cord (75). Otner evidenoe for oholinergio 
transmission in the cortex has shown that when Aoh is given I.A. 
or added looally to the cortex it increased the si~e of the 
spontaneous bursts of EEG, produced tremors and even oonvulsions. 
This indioates facilitation of oholinergic transmission at 
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oortioal synapse (tor references cf. 53), Koppanyi (53) suggested 
theretore that Ach affects oholinergic electrical activity of the 
cortex. Hypothalamic and reticular transmission may be also 
oholinergic. D-tuboourarine, a cholinergic blocking agent at the 
N.M.J., blocks upon intra-ventrioular injeotion the effeots of 
hypothalamio stimUlation on oardiao contraotility and acoeleration 
(Paiss, 70). Bradley (10) has shown that cholinergio oompounds 
suoh as DFP, can alert the mid brain and reticular formation, 
probably at the thalamio level. 
d. Physiological significance of other ChEs: 
While no other esters of choline except Aoh were gener 
ally found in the C.N.S., this is not neoessarily true elsewhere. 
Romologues ot Aoh such as Proh have been demonstrated in ox spleen 
(9). BuChE has reoently been demonstrated to be present in the 
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motor end-plate ~egion (44). The physiological role of these 
este~s as well as of BuChE or ~elated ChE i8 not known. It was 
suggested by Whittaker (78) and Karczm~ et ale (50) that the 
physiological role of BuChE might be to hydrolyze particularly in 
blood choline esters other than Ach, which may appear there as 
undesirable metabolites. BuChE may be also involved in intestinal 
motility and contractility (52). The physiological role of Prch 
is still obscure. 
IV. Determination of CnE activity: 
1. Methods of determination: 
More than one method has been used to determine CnE 
activity. 
a. Biological methods, in which Ach concentration was 
bioassayed on smooth muscle or on cat blood pressure betore and 
atter exposing the Ach solution to samples of biological material 
containing CnE. 
b. Chemical methods, in which the acetic acid liberated 
from hydrolysis ot Ach is determined' 
A. By titrating with an alkaline solution of known 
concentration using an indicator or by electrometric titration. 
B. Manometric methods: 
i. Warburg method is most oonvenient for follow-
ing the time course of hydrolysis of Ach, it is also most suitable 
for use in comparative and serial experiments. Ammon (3) was 
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first to use thia me~hod in assaying CbE activity. In thil method 
C02 is liberated from buffered bioarbonate system by aoetic acid 
formed during Acn hydrolysis by CnE ot the sample, C02 il then 
measured manometrically. 
ii. Van Slyke method is based on the same princip 
le as that of Warburg and employs different apparatus. 
iii. Microchemioal gasometric method has been 
sucdessfully applied to the study of the ChE activity by 
Linderstrom-Lang et ale (56). The principle of the Cartesian 
diver is applied in this method. 
.  
. 
C. A photometric method is based on the ferric chlo 
ride reaction with acetic acid liberated by CbE trom the substrate 
D. A histoohemioal method was first used by Koelle 
(51) and moditied by Holmstedt (45) and others. The method 
depends upon complex tormation by Ach thio-derivatives and cupric 
ion. By treatment with ammonium sulfide this oomplex changes to a 
black precipitate of euS which localizes the enzyme microscopical-
ly. In this method thio-derivatives ot Ach and Buch are used as 
substrate. for determination of true and pseudo ChE respectively, 
differential inhibitor. are used additionally. 
2. Units used in 8!2ressing CnE activitl= 
a. Naonmansohnta Q and A values are defined as follows: 
Q, mg Ach hydrolyzed in 60 minutes by 100 mg tissue at 20° C 
A. mg Ach hydrolyzed in 60 minutes by 1 mg protein 
b. Some investigators express enzyme aotivity in pl of 
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C02 evolved in 15 or 60 minutes by the sample. Figures for 
evolution ot CO2 can be used to calculate the amount of Ach 
hydrolyzed: 1 p.l CO2 = 8.1 Ilg Ach or 1 mg Ach = 123.5 pl C02 
c. Augustinsson's ct and b30 values are defined as fol-
lows: Cf= Aoh pmole destroyed/60 minutes/mg dry substanoe. 
b30 = CO2 pl/30 minutes. 
3. Faotors affecting the determination ot CnE activitlt 
a. Etfect of H ions concentration) at pH 2 the non-
specific ChE is oompletely destroyed; it starts to deoline in the 
alkaline range. Its optimum pH is 8 to 8.5. Optimum pH for 
.~ 
speoifio ChE is 7.5 to 8 (4). At pH 4.5 it is oompletely destroy 
ed. The stability in alkaline reactions of AoChE also seems to 
be less than that of BuChE. 
o b. Optimum temperature tor both AoChE and BuChE is 37 
to 400 C (38). 
t+ +~ ~~ 
o. Aotivators are said to be Ca ,Mg , Mn and some 
organic compounds (67). 
-tt' ++ Inhibitors are said to be Cu and Co (2, 67). 
v. Warburg method: 
1. The Warburg apparatus: 
Conioal flasks (15-20 ml volume) are used. Warburg mano-
meters are tilled up with Brodie solution (23 gm Nacl + 5 gm 
Na choleate in 500 ml water). Evan's blue dye is used in a 
solution having a density of 1.034, so that a 10,000 mm level 
difterence of Brodie solution~760 rom Hg. Contents ot flasks 
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are mixed by means ot .baking motor. The flasks are connected to 
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the manometers and are placed ln a water bath the tempera~. of 
which is constant and thermo regulated. 
2. The theorI ot the manometrlc technique: 
The condition. ot the •• say must be auch that in a reaction 
medium a certain gas ls elther eYOlved traa Or absorbed by the 
reaction ~tur.. At constant volume the gaa pressure can be 
recorded trom the change. ln the level ot manometer tluid. In th 
case of ChE, the sub.trat.s suGh as Ach or Blch are h7droly.ed by 
the enzyme.. The product. of h7drol~is are chollne + a.etic or 
benzoic acld. The acid i. then reacted with the bicarbonate and 
the resulting CO2 gas ls evolved. Its pre.sure is a measure ot 
the activity of the abE present in the reacting medlum. The 
chemical reactlons which ocaur are as tollows: 
1. AcChE+ Ol(OB,),N-Ci2-0B2-0-CO-CH, ~ AcOhE + choline + 
acetic aoid 
ii. CH,-COOK + B&HCO, ---t CH,-OOONa + 120 + CO2 
A thermobaroaeter tlask which contains 3 ml ot water and a control 
tla.k containing bioarbonate solution and sUbstrate solutioD ot 
the .ame concentrations as that added to the brain homogenates, 
are included in all experiments. Correctlons tor thermobaroaeter 
changes (due to alterations in temperature and pressure) and tor 
the non-enzy.m!c hydro11sis ot the substrate are made. 
!h. absolute volume ot CO2 liberated by the enaym10 hydro-
lys1s ot the substrate / unit time / mg brain tissue, can be 
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oalculated. In the cas. ot analysing brain tissue treated with 
lnhibitors, the percent of remaining ebE aotivity and ot ChE 
lnh1bi tion oan be caloulated provided control values are known. 
VI. Inh1bl topa ot ObE_ 
1. !be ors&nophoaphorus anticholin.at.rase~t 
The anticholinesterase agenta constitute one ot the tew 
classes of druge tor whioh a mechani.- ot action has been defined 
ln ter.ms ot inhibItion ot a apecific en.,... 
Priop to War I, Dixon and Ransom and Fras.r desoribed 
phar.macologioal aotions ot physoatigmine and demonstrated 
physostigmine mioais and slOwing up ot the heart as earl,. a. 
betore the turn ot the centu17. A t that t1me the.e investigators 
naturall,. did not mow that this substance is an anticholine.ter-
.. e or, in tact, that th1. mechanism ot aotion exists and the,. 
described actions of ph,.sostigm1ne a. muscarinic or stimulant to 
the parasympathetic syat ... 
The mechanism ot action ot physostigmine was studied atter 
the role ot abE was eluoidated aa alre.d7 described. Streus and 
Goldstein (1943) showed that pbJaostigm1ne and Aoh enter into a 
competition tor the aotive ait •• on the surtace ot the eDSJ.m8. 
Displacement ot Aoh by pbJaoatigm1ne nulllties the capaci t.,. ot 
the ens,me to hydrolyse Ach. 
Another important development was the demonstration ot 
anti-curare actlon ot physostigmine (Walker). The clinical 
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similarity between the loss ot skeletal muscle tone in myasthenia 
gravis and in curare poisoning led Mary Walker to conceive the 
idea that physostigmine which evoked a decurarizing action might 
be useful in the treatment of the disease. In 1934 she treated 
her first patient suffering trom myasthenia with physostigmine 
salicylate and observed dramatic improvement. 
Prior to War II, CbE was not ot wide interest; the advent 
ot the organophosphorus anti-cholinesterase agents at about the 
time ot War II which was due to Schrader's synthesis ot some ot 
these compounds brought new aspects to this area and CbE 
determination have become of practical importance in industrial 
health, crop protection and study ot insecticides, and in work 
on chemical wartare. The new agents served as antimyasthenics 
(TEPP, OMPA), or as war gases which .ere tirst synthesized in 
Germany and in England where Saunders prepared alkylphosphoryl 
tluoride (DFP), or tinally as insecticides (Parathion, EPN and 
Malathion). The last two compounds are the compounds used in the 
present study and they will be described later in some detail 
with respect to their chemistry, biochemistry and pharmacology. 
2. Stereospeciticitz ot organophosphorus anticholinesterases! 
The ObE inhibitors ot organophosphorus group can be given 
the general tormula proposed as early as in 1937 by Schrader, tor 
derivatives ot phosphorus acid with insecticidal properties (Fig. 
la). Biologically active compounds are obtained when in addition 
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to oxygen or sulfur, two similar or dissimilar substitients are 
bound to the phosphorus atom and an organic or inorganic acid 
residue is also present. Rl and R2 are oapable of almost infinit 
variation. 
The stereochemistry ot the anticholinesterases of the 
phosphorus group has been very little inVestigated although it is 
well recognized that enzrmes exhibit stereospecificity. Such 
specificity is likely to be the consequence of the asymmetric 
structure of the enzyme surtace. Recently the d- and 1- enantlo-
morpha of an asymmetric orgaaic phos~orus inhibitor of CaE were 
synthesized (1). It was found that the 1- isomer inactivated 
irreversibly four ChE preparations from 10 to 20 times taster 
than the d- form (1). 
3. Inhibition of ChE bl organophosphorus compounds: 
Wilson (77) has suggested a basic similarity between the 
interaction of Ach on one hand and of organophosphorus compounds 
on the other with ChE, despite the faot that the carboxyl esters 
suoh aa Ach are usually substrates and the phosphoryl derivatives 
are inhibitors of ChE. The foroes between Aoh and the enzrme 
are thought to be of three kinds at least (66), 
a. Ionio bond: The active surface of the enzrme protein 
contains a negatively charged site, the "anionic site" (77), whic 
reacts by cOQlombic forces with the positive eleotrio oharge of 
Ach (the cationic nitrogen), and contributes hereby to the 
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attraction, fixation and orientation of the substrate upon the 
enzyme surface. 
b. Covalent bond: There is also another group at the enzyme 
surface which reacts with the ester group of !ch by a covalent 
bond; this grouping has been referred to a8 the esteratic site. 
c. Van der Waals attraction between the substrate Ach and 
the enzyme. 
The suggested similarity between the affinity of organo-
phosphorus compounds and of Ach to the enzyme (13) can be 
demonstrated as follows: ., 
H-G G 
l l\ 
i. ff-G + CH)-COOR > R-O-C-O ~ 0-0 + ROH < I I (enzyme) (Ach) OR
3 OR) 
0 G 
II II 
ii. R-G + (RO) 2P.iwF ~ p-O + HP /\ 
RO OR 
(dialkJl phosphoryl enzyme) 
The bonding between Ach and the enzyme is easily broken down by 
hydrolysis. A. tar a8 the interaction between the enzyme and 
the inhibitor is concerned, labeling ot the organophosphorus 
32 inhibitors with P has shown that the bond between the enzyme 
and the inhibitor is 80 strong that it is not broken down by 
dialysis or by recr:fa t alization of the enzyme (16). In the 
inhibitor-enzyme complex the phosphorus atom represents a strong 
A, SCHRADER~ FOftMULA 
EMZYNE SU"FACr 
8. 
ACTIVATOR PHOSPHO~ATE 
FlooRE 1 
A. GENERAL FORMULA FOR ORGANOPHOSPROEIJS OOMPOOIDS 
B. REACTIVATION OF cum, INHIBITED BY ORGANO-
PHOSPHORUS OOMPOtnm. BY iir; CX~hE AGENT. 
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electrophilic center • This is a positive center whicn i. 
attracted to a negatively charged center at the enzrme surtace 
and theretore doe. not react with water to regenerate the active 
enzyme as readily as Ach-enzrme complex. 
It is possible however to regenerate the active enzyme by 
using nucleophilic reagents which are attracted to a positively 
charged center i.e. P atom ot the inhibitor. A large number of 
reactivators were studied, such aa hydroxylamine, pyridine and 
hydroxamic aoid methiodide (17). Reactivation occurs when 
because of coulombic attraction the reactivat&r can attack the 
phosphoryl group of the inhibited enzyme (Fig. lb). Hydrolysis 
of the phosphoryl group is ba.ed on the same principle aa Ach 
hydro~y.is in the ca.e of Ach-enzyme com,lax. 
i. 
ii. 
H 
H-6 + 
f ~ 
H-O + f-O 
OR) 
H-G ?'~_ f 
'- T + 1\-0 
(r.activat7RO OR 
or 
'" 
L~ 
> ,,-0 + OR 
BO OR 
) H-G + <~ I~ 
HO OR 
The organophosphorus anticholinesterase. that form comlexe. with 
the enzyme which are not easily hydrolyzed such as DFP, are cal 
"irreversible" inhibitor.. W.en given in vivo they ~roduee 
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inhibition such that the enzyme activity cannot be restored until 
new enzyme is synthesized. Other ObE inhibitors form ea8ily 
hydrolyzable complexes with the enzyme and therefore are called 
"reversible" inhIbitors, such a8 physostigmine. Toxicity caused 
by a reversible ChE inhibitor is temporary and normal activity of 
the enzyme is rapidly restored by its liberation from its complex 
with the inhibitor. 
4. Toxicitl of organophosphorus anticholinesterases: 
DFP as an example ot tl:1is group or agents produoes the 
following general effects (64): Motor!unrest, muscle twitching, 
tremors, ataxia, weakness, respiratory stimulation, salivation, 
miosi., bradycardia, defecation, diarrhea, and finally oonvuls-
ions which lead to respiratory depression and death. 
These symptoms fall into two groups: a) peripheral effects 
due to muscarinic stimUlation of respiratory and gastrointestin-
al tracts, and to nicotinic action on skeletal, particularly 
respiratory muscles, and, b) central effects. 
The meohanism inducing this toxic picture undoubtedly 
involves ChE inhibition. This in turn leads to Ach accumUlation 
which again probably oocurs both centrally and at the periphery. 
A direct toxio effect on the C.N.S. is considered of 
primary importance in CnE poisoning (23) and may be demonstrated 
by the following data: 
a. Michaelis et al.(63) demonstrated that a phosphonate 
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anticholinesterase causes central accumulation ot Ach. 
b. Karczmar and Long (48) showed that the mechanism involv-
ed in the protective action against TEPP toxicity of atropine 
and its congeners is both central and cholinergic in nature, sinct 
their protection against central toxicity parallels that against 
peripheral toxicity. 
c. Analysis of AcChE activitJ of pons and medulla follo'Vling 
TEPP administration indicated that following marked initial 
potentiation of respiratory retlex which was maximal a·t 10 to 12 
peroent inhibition of AcChE there wa~ a gradual but progressive 
deoline in the potentiated respiratory reflex in parallel with 
the tall of AcChE activity of regions vitally concerBed with 
respiration until respiratory failure was evident at 89 to 92 
peroent inhibition levels. The experiments suggested that the 
cholinergic transmitter Aoh, may be a factor in respiratpry 
control (62) 
d. As tar as the electrioal activity of the cortex i8 
conoerned the errects of organophospho.us compounds comprise EEG 
d •• ynohronization, convulsions and tloal11 quiescence. The 
convulsions may ultimately block respiratory activity which will 
have already been reduoed by muscarinic actions on the respirat-
ory tract and by the depressant effect of anticholinesteraso 
compounds on the respiratory centers and muscles. The de-
synchronization of EEG 1s the first Sign of action of the anti~ 
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ohol1nesteraae ooapounda on the aaoend1ng retloul.ar aotlva\1Dg 
81.t- O~ MONaal and MaDgun. Reoent studies bl Bradle,. (11) an4 
1:I1mw1oh (4J.) lnd10ate that chollnerglc drugs 40 not appe&J' to aot 
only on a meoban1am oont1"0111ng KEG pattern but 81ao em another 
meohan1am wb10h ls not oOlloerae4 with behavioural ohanges nob 
aa waketulneaa and al •• p. 
e. It baa been lIentloned el.l'11 •• that reouITeDt ool1atel'ala 
o~ the motoneuron and the Renahaw oell conat1 tute. a ohoUne.-g1.o 
ajn&pa •• 
OIl the other harl4. there aH 'ltome data which 1D41.oate 
that tox101't7 -7 not alva,.a depend e1ther oa g.neMl 01' oentral 
1nh1b1tlOD o~ abE. Frawley at al. (33) ha.a show that DFP 
&Xh1b1ted miniJD'lllD .,..ptoma when bra1n abE wu 1nh1blted by 92 
peNent, on the other band, Parath.Lon and TEPP Nduoed 
the aotl vi t,. to 20 pel'Cent and S1 percent ot normal N.peOtl .al,., 
conoomltant17 with a.vere aJlllptoaa. They oonolud.4 that vh11. 
brain abE 1nh1bl tlon _,. OODtl'1 but. to the alJllPt0a8 obael"nd. 
1t 1. not alva78 the ma1n cau •• ot death 1n the 0 ... o~ 
ph08phonate tox101t,.. 'l'.be •• data nsse.t that at oonwlal •• 
do ••• central abE lDh1blt1on 18 not equal w1 th the •• two 
oompounds, tbua, either oonw1alone are central but not clu. to 
central abE lnh1bltlon, or pel'1pheral and 100all •• d at N.M.l. 
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An important oonsideration il whioh part ot the brain was analyz-
ed tor the ChE activity. Small inhibition at one particular lite 
does not necessarily mean that equally Imall inhibition ocoured 
at all sit.s. The data ot Frawley et al are also in disagreement 
with the results or Metz (62) showing that respiratory tailure 
with TEPP was evident at 90 percent inhibition ot medullary AcChE 
and with the results ot Karczmar and Long (48) whioh were already 
desoribed. 
5. Brain Barrier and orSanophosphorus antioholine.terase.: 
It has been known long that sOme compounds penetrate more 
easily than other blood brain barrier. This i8 true tor example 
ot tertiaries which can croas the barrier more readily than the 
quaternary amines. This has been related to dirterenoe. in lipoi 
solubility. It haa also been known long that cer'ain substanoes 
cause central ettects and at the .ame time damage blood brain 
barrier to such an extent that the damage can be visualized with 
vital .taining by trypan blue. Tertiary OhE inhibitors produce 
central etteots with~ut destroying to any extent the blood brain 
barrier (68). The penetrability ot sultanilamide, ,_hieh i_ 
measured by calculating the ratio ot this substance that pen.-rat 
into the brain to that in plasma, into the brain wal found to 
inorease with inorea.ing permeability of blood brain barrier. 
Paulet and Andre (69) used this teat to investigate the relation-
ship between the anticholine.teraaic ertect and the ohange in 
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permeability ot blood brain barrier of some organophosphonate 
oompounds. Tney tound that some antioholinesterases suen aa 
Parathion and OMPA increased tne permeability of blood brain 
barrier, and that tni. property appeared to be independent trom 
the antioholineateraaic activity ot tnose sUbatanoes. 
6. Metabolisll ot the organophosl2horus antioholineaterases: 
In 19S0, Duboia (24) and Gardiner (36) reported metabolic 
oonversion of organophosphorus oompounds to antioholineaterase 
agenta. Casida (16) and Cage (1$) have shown that many organo-
phoaphate esters are toxic in vivo and yet ineffioient as ChE 
inhibitors in vitro; thus theIr metabolio oonversion to more 
aotive anticholineaterasea can be auspected. Metcalf and Maroh 
(61) used the Warbure teohnique to determine the activity or EPN 
and Malathion incubated with liver slioe.. House fly head 
enzyme was aensitive to those oompounda after incubation. Para-
thion metaboliam naB been ahown to result in an isomerization 
between the thiono-sulfur and tbe ethoxy-oxygen, rendering it a 
more potent antioholinesterase. Thus, metabolism in vivo, 
catalyzed frequently by liver enzymes may lead to tormation ot 
more toxic oompounda. Th. opposite oan ooour also, and is a 
major oonsideration in the evaluation of modern inseoticides. 
Malathion,an insectioide of extreme importanoe at present, has 
tne advantage or being mucn less toxic to mammals tnan to insects 
beeaus. it is broken down in vivo to inaotive compounds a8 snown 
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in the hen, mouse and ~oach (59). In vit~o studies by Cook et a1 
(18) showed that Malathion is altered very quickly by ~at 11ve~ 
when it is hydrolyzed at the diethyl succinate group to a compoun 
which is inetrective and mo~e water soluble. This breakdown or 
Malathion may be inhibited by certain organophosphorus compounds. 
It has been shown by Murphy and Dubois (65) and by Cook (19) 
that EPN as well as some - but not all - other o~ganophoaphorus 
compounds inhibit Mala_hion-detoxitting live~ enzyme. The 
~.oove~y or EPM inhibited liver enzyme oocurs in a matter ot a 
rew days. This point or great perti~enoe to the present researeh 
will be discussed in greater detail subsequently. 
7. Biochemical and pharmacological action. or EPN and 
Malathiom: 
.m wu synthesized during the war and shown to be an 
insecticide belonging to the general class ot compounds referred 
to a. organophosphorus insecticides. Chemically it il O-ethyl-
O-P-nitrophenyl thionobenzene pho.phonate (Fig. 2). The technica 
EPN 1s a dark amber liquid, soluble in most ot the oommon o~ganic 
solvents and stable at ordinary temprature. 
EPN produced ma~ked inhibition ot human erythrocyte. CnE 
slowly increasing with tim. (42); deoreale ot ChE activit7 to 
53 percent or initial activity occured in 200 to 300 minutes. 
CbE inhibition by EjN i8 irreve~.ible (42). EPM lacks high CbE 
inhibitory action in vitro. In vivo, the intoxication i8 cholin-
t'I~ 
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ergic in nature and exhibits C.N.S. manifestations. In general, 
intoxication symptoms are those characteristic ot anticholin-
esterale agents. EPN is considered as one ot the potent toxic 
organophosphorus compounds and its LDSO in dogs is 20 to 30 
mg / Kg orally. 
Malathion is chemically O,O-dimethyl S-(1,2-dicarbethoxy) 
ethyl dithiophosphonate (Fig. 2). It was Iynthesized by Casaday 
(14). r1alathion is a yellowish oily liquid, having a strong 
smell ot garlic, slif{htly soluble in water, miscible in most 
commonly employed organ1c solvents an4 stable at ordinary 
temperatue and pressure. 
The pharmacological action ot Malath10n seema med1ated by 
the inhibit10n or tissue enE; the ligns ot toxicity atter a large 
single dose in experimental animals are almost exclusively 
characteristic of oholinergic intoxication. Among those are 
excessive lalivation, depression, tremors, convuls1ons, coma 
and death. Its inhib1tion ot ObE is irreversible (40). It baa 
a relatively low mammalian toxicity with an exceptionally wide 
range ot activity against insects. It is one ot the tew organic 
phoaphonate insectioides that 1s considered aate enough to 
justify availability in commerce tor general insect oontrol uae, 
It is weak anticholinesterase when compared with Parathion and 
EPN. It wal stated that in dogs, Malathion given I.V. inhibited 
plasma ChE more than RBG and brain CbE (40), while Parathion and 
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EPN inhibited more RBC and brain CbE. It was also said that an 
ettective dose of l'1alathion increased blood pressure (40) follow-
ed by respiratory failure, Metrazol and artificial respiration 
failed to revive the animals. 
8. ~ot.ntl.tion bl oombination of ori&nophosphorua anti-
ohol:lnestex-uu: 
The possibility exiata that a worker may be exposed to 
two or more insecticides on tue same or difterent day., and that 
intoxication may aooidentally ocour by ingesting several difteren 
." 
food products, eaoh containing a difterent insecticide. Thia 
prompted F'rawl~y et al (34,3$) in 1957, to oarry out a aerie. ot 
experimenta on the additive aotion ot EPN and Malathion. The 
data ahowed potentiation of aoute toxioit1 ot EPN and Malathion 
when they were administered simultaneously to dogs. Potent-
iation was leaa marked in rata. Potentiation ot inhibition ot 
RBC CbE was noticed also. Frawley et ale auggested that the 
meohanisM ot potentiation ia not a chemical reaction between the 
two phosphonates, but that the potentiation ot ebE inhib1t1on 1n 
RBC 18 a results ot a prior reaotion ot one or both ot tb.e 
compounds with another biologioal system. Sinoe it waa demonstr~ 
ed that phosphonates are enzymatioally detoxified and t~at this 
can be blocked by oertain other pnospbonates, Oook et ale (19) 
sugge.ted that this is tne baais ot the potentiation ot Halataion 
by EPN. Rosenberg (73) confirmed tb.at EPN potentiate tox1.oit1 
28 
ot r!alath!on when th.. two oompounds ares! yen orally simultane-
ous 1y ;0 l"ats. TIe showed also that combinations of Malatblon 
with ONPA, Parathion, DPP or with physostlgmine show minImal 01" 
no potentiation. Combinations ot EPN-Faratnion, E:)l~-Oi"iPA and 
O!'1PA.Paratb.lon exhibIted no potentIation of toxicity (7.3. 7L~). 
Beaidea potentIation ot CUE Ulhlbltion, pharmaoological potent-
iation at epelfic neuroetteotors, such. &8 vagal, ganglionic, 
neuromyal and at tn. C.N.S. w •• also dem6nstrated (39). 
Howev.~ botn potentiation of enzymio inhibition and of 
.~ 
neuroettectoll toxioity need not be entirely due to ttle meohanism 
IUgs •• tedof Cook et a1. (19) alnee it was snown earlier tilat 
even quatern~7 compounds which should not be hydl"olyzed by tne 
.nape. desoribed by Cook (19) also potentiate eaoh othel' (Lands, 
Hoppe, Kareamu and Arnold~ $$). TtUa 18 one ot the points tnat 
led to tne pre •• nt r.ae~oh and w111 be discussed mOl'e 1n detail 
in tn8 next aeetion. 
VII. Tg8 isrR2!. 2' tn! weist atuS,. 
A jerie. o£ ayntuetio organopi:loapno1"Us compounds, b •• ides 
being employed as pnarmacologioal tools, are used as cno1lnerglc 
agents In therapy and as inseoticidel. Ta.1I' applioation in 
agriculture Is oontinuously expanding. Many que.tions regarding 
their pharmacologioal act10n must be Answered, for the protection 
ot the manu,tacturer as well .s tn.e consumer ot tn. treated rood. 
ChE 1nvestigations were d.ai3ned to evaluate the relationship or 
~ 
inhibition to symptomatology_ A ~ecent demonstration trom ou~ 
laboratories and from Fede~al Food and Drug Administration that 
certain anticholineaterase W~ gases and inaecticides potentiate 
the toxioity of eaoh other rather than act merely addltlYely Is 
to be conaidered in view of the possibility of aimultaneoul 
expoaure to two or mo~e ot theae compounds. This phenomenon has 
p~ofound theoretioal and practioal implications and points out 
the need for oaution in the USE of drug oombinations in the field 
or therapeutios and tor additional investigations in this fre-
quently overlooked phase ot pharmaco~ogy and toxioology, parti. 
cularly since organophosphoru.s oompounds ot particular interest 
in the present study, EPN and ~alathion, are among taose which 
are in greatest use in agriculture. 
The potentiation was however inadequately studied. 
There was no previous 8ystematic investigation ot these two 
compounds as to the dose-effect ~elationship ot the1r antioholin-
eateras. act1on, the type of tbe1r interaction with the enzyme 
or to the relationship between the extent of inhibition parti-
oularly at strategio er£ector sites. and toxioity. Potentiation 
ot CbE inhibit10n waS generally demonstrated with reterenoe to 
blood enz~ne8, and not enQugh data are available as to 0hE 
r •• ponse of other tissues, particularly of the G.N.S. Per ae 
potentiation ot inhibition ot the blood enzyme cannot account 
tor the rapid death observed, although it is generally thou§;ht 
30 
that tne inhIbition of this enzrme il ~eaponslble to~ the action 
ot the individual compounds and a180 tor the potentiation ot the 
toxioity ariSing trom the admini.tration of their combination •• 
Finally, inbibltlon ot detoxification ot one compound by 
by the otner Wal the eXplanation ottered tor tile potentiation of 
the .n&1II1c inhibition and of tonolty ari8ing; from oomblned 
acJmlnlltration ot tne •• compounds. This explanation naturally 
do •• away with the difficulty of underatandin6 the mechanism 
whep.by en_lvally slml1a1' compound. whicb. snould react with 
identical radioals ot the enzyme act·~m!l>re tllan addltivel,.. 11ow-
evel", indication. tllat anothernlS'chanisr.1l-ms 'involved were' 
alpeady mentioned. 
The abo •• qu •• tions nece •• ltate a detailed study of inter-
action. between EPN, Malathion and the enzyme in vivo and in 
v1tpo wIth l'eg&1'd to potentiation of Inhibition ot a.M.S. enzyme, 
dependenoe ot inhibition on EPN and Malatb.ion metabollam, and 
type ot !PH and Malataion lntaractlon with the onE. It Val a180 
nec •• eary to reexamine tbe h1Potb •• la ot COok, and to att"pt 
it n.a.8.~1 to .u~g.at alternatlYe •• enanism. to~ the potent1. 
\'lilile 
atlon. F1nally,~tne pre.ent re •• arch i. not conceived to elucid-
ate pre.en~ ,unoertalnlt,. ot tne mechanism ot oent!'al t1-ana. 
mi •• ion 'it mtlJ ,.ield additional olue. for tne understanding 
ot the tunction ot ChE in the O.H.!. 
CHAPTER II 
PROCEDURES 
I. Technical -PEroacn to tn. Ere.ent studl: 
The two compounds in question, EPN and Malatbion, were 
given singly and in combination and studied in vitro as well as 
in vivol Warburg manometric technique was ueed for tne measure-
ment of abE activity. In vivo studies were carried out b,. 
injecting the compounds into tne temoral vein of anesthetized 
animals and intraJugularl,. and intraventricularl,. to tne "upper 
animal". The "upper animal" (ct. intra) technique was used to 
suppll intormation .s to whether or not tne metabolism of these 
compounds is necessarl tor their actions. 
The in vitro stUdies were carried out by adding compounds 
to brain homogenates. In other instances thel were incubated 
with. liver, then added to brain homogenate. The in vitro studi.is 
had as their purpo.e first, to inv •• tigate the conditions in 
which. the potentiation mayor may not occur, particulatly with 
regard to the necessi.tl ot liTer incubation tor pot.entiation. 
Secondly, it vaa ascertained whether or not the enzJMic inhibit-
ion bl compounds in question was irreversible aa suggested bl 
Hazleton et al. (40) and thia was tested bl dialysis and dilution 
technique.. ae.ides theoretical implications ot tb.1s the 
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irrevelibility or their action renders the measurments or inhibi~ 
ion ocouring in vivo more reliable, ainoe it precludes reverai-
bility of inhibition during meaaurments. 
II. Preparation of the animal (general): 
Doga were uled for the present study. They were anes-
thetized with an average dose of 30 mg/Kg of Na pentobarbltal, 
given I.P. The average weight of the animals was 8 Kg. The 
femoral vein was expo.ed for I.V. injeotion of the compounds In 
question. At a certain time atter the injection, the animals 
were lacritied by dividing the spinal cord at a level below the 
medulla. Tbe lkull wal opened and tbe brain wal taken out foro 
biochemical analYlis. In lome instances, the brain lamples were 
kept in the rerriseratoro and were analy.ed tbe followlng day. 
III. PreparatIon gt 'be "uppe. anImal". 
This Ipecial anImal proeparation wal done ror the purpole 
ot studying the etfect of tbe compounds 1ft question without 
compounds being ciroulated through tbe liver or any other vilcera 
organs. The dogs were aneithetized al mentioned above, the 
trachea wal expo.ed and a tracheal oannula was inlerted tor 
arotiticial re.piration. Tbe aorta va. 11gated above the level 
of the hepatic artery. Thil W.I done by making a Imall inci810n 
in the diaphragmatic membrane through which a ligature was 
clamped on the aorta. To reaoh the diaphragm, an Inci.ion was 
made in the abdomen, then the me. enteric viaceral membrane was 
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separatea from the abdominal wall. In this way, hemorrage and 
blood loss was avoided to a great exyent. Subsequently, the 
animal va. kept under artifioial respiration during the remainder 
of the experiment. At the end of most experiments the state of 
aortic ligature was ohecked to asoertain the success of this 
form of hepateotomy. Additional indioation of the sucoesa ot 
the procedure was that the blood vessels of the liver were always 
noticed to be collapsed. 
The drug. were administered to the "upper animal tf either 
intrajugularly in which ca.e the external jugular vein was 
exposed tor that purpose, or intraventricularly. In the latter 
case a small hole {IX} 0.2) wal drilled out in the skull and 
26 gauge needle was inserted into the brain ventricle. When 
injecting the drug, spinal fluid of a volume equal to that to 
be injeoted was withdrawn. 
IV. Preparation for tbe liver inoubatioq' 
Duboi. technique (24) tor liver inCUbation ot the organo-
phosphorus compound. wa. tollowed. The incubation medium for in 
vitro studies contained the following components ia the conoen-
trations indioated: Dog liver homogenate 2.$ percent; dlpho.pho-
pyridine nucleotide (DPN) 0.1 peroent, nicotinamide lXlO-3 M, 
and phosphate buffer at pH 7.2. In oertain experiments DPN was 
excluded from the medium. The inoubation medium to~ the in vivo 
study oontained the following components: EPN, 1 mg/gm liver 
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homogenate and Malathion, 100 mg/gm liver homogenate; DPN 0.8 
percent; nicotinamide 8xIO-3 MJ and phosphate buffer at pH 7.2. 
Usually, EPN and Malathion were incubated for 2$ to 30 minutes 
at 380 C then added to brain homogenate in vitro or injeoted 
into the "upper animal". 
The ooncent~atlon of EPN (lmg/gm) waa seleoted so as to 
inhibit only the liver enzyme 1n its inCUbation medium and not 
to protect Malathion detoxification by ita own medium when EPN 
and Malathion were used in combination following incubation, in 
vitro or in vivo. In tact, the oono.ntration used inhibited 
about 90 percent ot the liver detoxifying enzymes (65). In 
80me in.tance., difterent concentrations of EPN and Malathion 
were allO used. 
V. Dl1ution technique' 
The inhibited brain homogenate was dl1uted tour or more 
time.. Solutions ot varlous dilutions were analyzed to determine 
their ChE aotivity and percentual inhibltlon ot OhE obtained 
at various dilutions va. compared. 
VI. Diallsis techn1gue: 
Microdlaly.i8 technique a. de.cribed by Craig (20) V&I 
used. Pho.phonate-inhibited brain homogenate was placed into 
a dlalY8is bag. Inside thIs bag a glasl rod smaller in diameter 
than the dialysis bag was placed so that the layer of the 
dialyzed solution (inner medium) would be of very small thickness 
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Dialysis bag and its contents were placed in a container having 
bicarbonate buffer (outer medium) identical with that used for 
homogenizing the brain. This allowed better exchange of ions 
between the outer and the inner media, and eliminated the 
necessity of stirring (20). Dialysis was carried out for a 
period of 12 to 12 hours and the brain tissue was analyzed to 
determine its ChE activity before and after dialysis. 
VII. Preparation for manometrio analzsis: 
1. Procedure: 
calibration waa made for each Warburg flask and its 
manometer, and the flask oonstant "Kif waa calculated. Homogen-
ates were diluted in bicarbonate buffer containing 0.02$ M Na 
bicarbonate and 0.005 M MgC1Z. Bicarbonate was gased from a 
cylinder containing a mixture of 5 percent CO2 and 95 percent N2. 
lX10-3 MAch and lxlO-2 M Bzch were the substrates used to 
determine AcOhE and BuChE activities respectively (cf. August. 
insson, 1951). The brain tissues analyzed were gray and' white 
matter of the oortex and of the medulla. Forty five to $0 mg 
brain tissue homogenates, in 2.1$ ml of the bicarbonate bufter 
were plaoed in the main oompartment ot the Warburg flask. The 
final volume ot solution in each flask was .3 ml. A flaak 
containing only bioarbonate buffer ana the substrate and another 
flask serving a. thermobarometer and oontaining .3 ml of water 
were included in all experimental series. All the flasks were 
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then conneoted to their manometers and placed in water bath at 
380 C. EquIlIbration was oarried out tor 15 minutes, the C02 
and the N2 gas mixture was bubbled through for 5 minutes, the 
air trapped inside the manometers was then expelled and all air 
vents ot the tlasks closed. BrodIe solution was adjusted in the 
right arms ot the manometers at the 150 ml mark and zero readings 
in the lett arms ot the manometers taken. The substrate was 
then tipped into the main oompartments ot the flasks and the 
shaking motor ot the machine turned on. Manometers were read 
eve:ry 5 to 10 minute. tor a total ot.~60 minutes, solution was 
adjusted in the right arm at the 150 mark and the left arm level 
itleuured. 
2. Numerical example of the analytical results: 
Pig. 3 show. the evolution ot CO2 during 60 minutes 
period in the oase ot 100 mg homogenates 01' cortical gray matter 
and ot medulla, Aeh substrate. The oaloulation ot the tlasks 
constant "K
e02" and ot the C02 evolved were carried out as 
tollows. 
a. The calculation at the tlask constant tor C~2 I 
(flask volume in p.l - tluid volume in ,Ill) X t + fti 
+ (fluid volume in p.1X 0<: CO2) 
pO 
gas volume in pl • .!fl.+ tluid volume in pl. Q'C C02 
)JL CO2 
EVOLVED 
180 
x MEDULLA 
• CORTEX 
10 20 30 40 
MINUTES 
FltJJRE .3 
x 
• 
50 
Jm>ROLYSIS OP ACH BY BRAIN CBB 
37 
60 
KC02 = tluk: oon.tant tor C02 gu 
ot02 - 0.S67 at 37° C 
'f _ 'f0 1" t = 273 + , 
pO = 10.,000 
Fluid volume =)000 pl 
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b. The oaloulat10n of C02 .volved 1n p~t1me/dry welght 
of tl.sue (Aoh substrate)' 
F1 .. k #1 Flalt #2 Flaak 113 Flaak A 
'lb...... Bl0&1'bon- Conloal MedulluJ 
_om.ter .f.'. ts..8ue tl.aue (<<f.B.) . 
It = 1.8 It = 2.0 K = 2.0 
12 Man_.trl0 dltterencel 7 40 minut •• 43 99 
T.B. subtraotion 
Mult1plloatlon b.1 Ke02 
Corr.otlon to.. non-
ensJa!e hl4PolJ.18 
ot .lob 
Pal COallOO as drJ tl •• u'; 40 m1fiute. 
S 
9 
36 92 
72 184 6, 17S 
67.5 
To .auve tile Tul&b11t'1 of blMb.eJd.oal data, a 
statl.tlcal analrsi. ... oarrle. out with regapd to cortieal and 
medull8l",. OnE acttnty (Table 1). Fitteen dog. wer. atudied In 
tb1. aerlea ot experiment. over .. p .. lod ot 1 y.ar. In the 
0". ot eacb dog .3 to 6 det ... lnatlon. ot the medullar,. and 
cortloal enZ7118 w.~. made with Ach ... substrate and the r •• ult. 
averaged. Tbe variabilit,. ot 6 determlnattons from tbe .... 
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animal was ± 0.06 p1 C02' in tne caee of all 15 doga the value. 
tor cortical and medullary ebE aotivity were 27.6 ± 0.46 and 
64 ± 0.71 pl C02. Thu. tne variability ot tne manometric data 
tor 15 animal. over a period of one year waa le88 than 2.0 
percent lndicating hlgh reliabilIty ot the method. 
Tne mean 
Standard 
deviation 
'lABLE t 
STATISTICAL ANALYSIS OF BRAIN CBE 
ACl'IVITY Dm'ERMINED IN NOBMAL ANES .... 
THETIZED A.NIMALS. ACH SUBSTRATE 
1.$ DOGS. IN THIS EXPEBDtD'l' AND II' 
ALL THE SUCCB:BnN'G ONES EACH SAMPLE 
WAS DUPLICATED. 
Plot eOa/100 mg dry 
vt. ot eOl'tical 
ti88ue/ 40 minute8 
28 • .$ 
)1.5 
26.5 
26.0 
26.$ 
26.0 
26.0 
28.0 
28.0 
26.0 
27.0 
28.0 
29.0 
26.0 
)1.0 
27.6 
± 0.46 
Plot C02 evol ved/100 
as drr wt. ot .edulla-
P1 t18.ue/40 minutes 
± 0.71 
I. In vitro Itudy: 
OHAPTER III 
EXPERIMENTAL RESULTS 
1. Enzl!atio inhibition hi non-inoubated and liver-
incubated EPK: 
Di~t.r8nt conoentration. of non-incubated EPN were added 
in vitro to brain homogenate. Also EPN inoubated with liver 
homogenate with DPN added, al well as EPN incubated with liver 
homogenate alone were adaed to bra1n~homogenate. As indicated 
in Fig. 4, non-inoubated EPN haa weak inhibitory action on brain 
ObE in vitro, while percentual inhibition of OnE wal much higher 
when EPN was incubated with liver and DPN. On the other hand, 
there was no definite inore ... in anticholinelterase activity ot 
EPN when this compound waa incubated without DPN. 
2. Irrever8ibikity ot the CbE Inb.ibite4 by EPN: 
The character ot the interaction betw.en EPH and the 
enzyme OnE ... studied by 'e.ting the irreversibility of their 
bonding compl... PhJlical rather than chemical meanl were us.d 
for thia purpose, namely, 
a. Dikution tecnniguel 
The resultl or tb1a study are shown in Fig. 5. They 
indioate that dilution hal no errect on the bonding between EPN 
40 
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Illa1BA.TED AHD lfOll-IlftuBATJID BPI'. 
BACH POINT HBPRESEftS Alf AVERAGE VAWE OF 
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43 
and CbE irrespeotive ot EPN oonoentration. 
b. Diallsis technique. 
The a~~aohment between EPN and CbE waa not destroyed 
by dialyais ot trom 24 to 72 hours (Fig. ~)f luggesting again 
that EPN inhibited brain ObE irreversibly. 
The results listed under Ca> and (b) indleate the 
rellability ot the bioohemical determinations carried out in vivo 
3. Enzl!atl0 inhlbition bI non-!ncubated and bi liver-
Ingubated M'tathionl 
Malathion alone, as well as Malathion incubated with 
liver homogenate waa added in ditterent ooncentrations to brain 
homogenates. The ettects on brain ebE are shown in Fig. 6. 
Malathion inhibited brain ObE at the I~o ot 0.8 ~ 10-5 MJ inhibit 
ion ot CbE was higher when Malathion vaa not incubated than when 
it waS incubated with liver homogenate. 'fhe results indioate 
alao (Fig. 6) that M~athion loat it. aotivity to the a .. e extent 
whether it was incubated with live. homogenate or with liver 
homogenate and DPN. 
4. Malatg10g ina!tlvatiog bl liver homosenate. 
To study the rat. ot Malathion inactivation by the liver 
Malathion val incubated with dog liver homogenate in a conoen-
tration of 50 mg/gm liver. Incubation was carried out tor 0, 15 
and 30 minutes. Atter each period, the incubated Malathion Wal 
added to brain homogenate and brain CbE activity determined. At 
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PIGURE 6 
IN VITRO INHIBITION' OF BRAD CBE BY LIVER-
INCUBATED Alm I'ON-IliCUBATED MALATHION. 
EACH POINT REPRESElfTS AN AVERAGE VAmE OF 
FOUR DETERMINATIONS FROM FOUR DOGS. 
ACH SUBSTRATE. 
4S 
zero time, Malathion inhibited 80 percent ot the brain OhE, while 
atter 30 minutes ot incubation with liver homogenate it inhibited 
only 34 peroent ot brain Ohl (Table 2). Thus, when Malathion-
liver ratio i. about 1120 Malathion "halt lite" is about halt 
hour. This sugg •• ta a relatively rapid destruotion ot Malathion 
by the liver enzyme. 
s. Malathion-CbE interaetionl 
A. was done with lPN, d1alysi. and dilution technique. 
were used to study the type ot interaotion ot Malathion with 
brain OnE in vitro. 
a. DI1utiog technique. 
The results ot this study shown in Fig. 7 indicate 
that tne binding between the inhibItor and CnE waa not de.troyed 
by dIlution. Thi. sugge.ted an irrever.ible type ot interaction. 
b. Diall.is tecan11e •• 
The result. shown in Fig. 1, oonfirmed the ob.ervation 
obtained by the dilution technique, ot the lrrever.1bil1ty ot 
Malathion inhibition ot Brain OnE. Again thl. shows the rell., 
ability ot the method used tor measuring in vivo inhibit10n by 
Malathion. Moreover, thea. data in conjunotion with similar 
results obtained with EPN, indicate at least a certain degree ot 
similarity between EPN and Malathion with regard to the type ot 
their interaction with CbE. 
6. In vitro anticholin,ste£a.e ettect ot combined addit1~n 
TABLE II 
MALATHION INAO'1'IVATION BY LIVER HOHOGEIATE 
IN VITRO. EACH VAWE REPRESENTS AN AVEBAGE 
VAWE OF FOUR ANIMALS. 
Time ot incubation 
in minutes 
o 
5 
15 
30 
ot EPI and Mala'B&on. 
Percent ObE inhibition 
in vitro (Ach substrate) 
80 
70 
56 
34 
a. Combination of tne non-incubate. compounds: 
46 
Non-inoubated EPN and Halathion were added in vitro 
to brain homogenate, aing11 .a .. 11 as 1ft oombination. Atter 30 
to 60 minut •• the activitJ of brain CbE was determined uaing Ach 
substrate in each oase, trom which extent ot inhibition was 
calculated. Table 3 and Fig, 8 ahow percentual inhibition of 
brain CbE re.ulting trom cambiae. ettect of ditterent concen-
tration ot EPN ud Malathion. It appeued that the ettect ot 
combination of non-incubated compounds in vitro waa .ere17 addi-
tive. In tact, in certain ca.e. ObE inhibition produced was 
somewhat le.8 than additive (Table 3). It .eemed that when high 
concentration ot Malathion was added in combination with EPN to 
brain homogenate, the inhibition appeared to be equal to ObE 
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IN VITRO tlHIBITION OF BRlDl CBE BY 
EP:W AND MALATHION AND THEIR COMBI1fA!IOlf 
EACH VALUE REPRESENTS AN AVERAGE VAWE 
OF FOUR DOGS. ACH SUBSTRATE. 
48 
The eompound Ooncentration Percent ChE inhibItion bJs 
EPN 01' EPN and 
Malathion Ma.lathion 
sIngly cOJlb1Datlon 
Malathion ).2 10-Sr-t 80 
10·~ 80 EPH 4.0 :to 
Malathion 2.2 10·Sx 80 
EPN 2.0 10-~ $0 95 
Malathion 2.0 10-~ 78 
7.5 lO-~ 8$ EPN 2$ 
Malathion 0.2 10·5M 42 
lO·$X 68 BPI 6.5 28 
100r-------------------------------------------~ 
~.I NHIIITION 
OF ACHf 
80 
CORTEX MEDULLA 
60 
40 
o 
FlOOD 8 
IN VITRO EFFECTS, ON BRAIN ORE, OF COMBINATION 
OF NON-INCUBATED OOMPOUNDS. ACB SUBSTRATE. 
EACH VAtUE REPRESENTS AN AVERAGE OF FOUR 
DETERMINATIONS FROM FOUR DOGS. 
49 
so 
inhibition produced by Malathion alone. This may be due to 
Malathion having higher atfinity to brain ahE than EPN. and 
preventing the action ot EPN at ce~ta1n sites ot CbE molecule. 
It may be a180 that the CbE inhibition br EPI i. a alow process 
allowing therefore !4alathion etrect to predominate at the time 
(30 to 60 minute.) that the reading was taken. 
b. Combination ot liver-inoubated oOBPounda. 
EPN incubated with liver and DPN and liver-incubated 
Malathion were added to brain homogenate lingly and in combina-
tion. The activitf ot brain ehE va"~tben detel'lllined and it. 
inh1bltion caloulated. The rHults obtained (Fig. 9) indioate 
that combination ot EPN incubated with liver and DPN and liver-
incubated Malathion resulted in a potentiation in vitro of the 
brain CbE inhibition. Thi. might b. explained by Cook t • theory 
it we were to assume that EPH inhIbIts detoxifIcation ot Mala-
thion by the liver homogenate added in vitro in th •• e experiments 
However the question arises as to whether or not thia 
il the only mechanism that functions here. Potentiation occurad 
also when incubated MalathioD wal added to brain homogenate 
atter the addition ot ErN. The concentration ot lIver Incubate4 
with Malathion val selected so that moat Malathion should have 
been deatroyed. The concentration of EPN (0.2 to 0.8 mg/gm liver 
vaa selected 10 as to inhibit the liver enzyme in its own 
incubation medium and not to protect detoxification of Malathion 
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IN VITRO EPFBCTS # ON BRAn CRE, OF aOHBINATIOlf 
OF DIP'FBREN'r CONCEITRATIONS OF LIVER-IN'OOBATBl> 
AND NOlf-INOOBATED COMPOUNDS. ACH SUBSTRATE. 
BAOH VAWE REPRESENTS AN AVERAGE OF POOR 
DETERMINATIONS FROM FOUR DOGS. 
S2 
br ita own medium atter combination with EPN sample; indeed, at 
the.e concentration of EPN inhibition ot the~alath1ona •• • ot 
it. own homogenate wal inoomplete and no EPN wal lett over to 
protect Malathion trom detoxitioation (or. P. 33) 
The pertinent reaults were as tollows: 
lS percent brain abE inhibition br EPN, 0.8 mg/gm liver 
12 percent brain CbE inhibition br Malathion, 20 mg/gm liver 
6S percent brain ebE inhibition br EPN-Halathion combination. 
When ooncentration or Halathion was kept con.tant and 
EPN concentration waa lowered, poten~jation Itill occuredl 
4 per~ent brain CbE inhibition br EPN, 0.2 mg/gm liver 
12 percent brain ChE inhibition by Malathion, 20 mg/gm liver 
40 peroent brain ebE inhibition by lPN-Malathion combination. 
II. In vivo studie!1 
A. Sinsle administration: 
1. 81gsle I,V. administration I 
a. ltV. a4m1niatration ot IPNl 
A 'iatamatie Itudy ot the in vivo etreota ot EP. 
and ot it. dose-ettect relationship was oarried out. Non 
ertective and lethal do.es were also u.ed. Fig. 10 indicatea 
that EPN exerts in vivo anticholineateraae etrect on brain enzyme, 
and that thIs action tollows a clear cut dose-errect relationship. 
EPN appeared as a rather in vivo potent inhibitor and ita anti-
choline.terase ettect tirst appeared at a dose or 2 to 3 mg/Kg 
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54 
(Ninety to 100 peroent inhibition vaa obtained with 10 to 12 mg/ 
Kg) ot EPN. 
Table 4 ahows the antioholine.terase etteot ot 
EPN with respect to the death trequency in anesthetized dogs. 
The death caused by toxic doa.s seemed to parallel fair ely close 
the level ot inhibition ot brain AcChE. Death did not oocur 
until the inhibition reaohed about 90 percent of the normal 
aotivitJ ot the enzJme. Cholinergic symptoms suoh as deteoation 
salivation. muscle twitohea, convulsions and respiratory embar-
rassment were observed witp lethal d~8e. ot EPN, milder oholin-
ergic symptoms al.o were observed with lower etteotive doses ot 
EPN (Awad and Karozmar.8). 
were 
Brain samples trom animals given EPN I.V. added to 
were ~ 
brain lample trom untreated animal, the two samplel then homo-
A 
gen1zed together and CbE activity me.lured 1n this mixed sample. 
In this ca.e the enzJme ot the untreated brain lample was not 
inhibited .1 ,hown im Table 5. This indioatea that no tree 
phosphonate compound, were present in the brain tissue, ot animal 
given EPH in vivo. 
b. l,V, admini,tration ot Ma,athionl 
In a similar way experiments were carried out 
with Malathion. Fig. 11 indicates that Malathion has an anti-
cholinesterase etteet on brain enzyme in vivo which tollows a 
clear cut dose-ettect relationship. Malathion 1s a weak inhibit-
TABLE IV 
LETHALITY AND BRAIN CBE INHIBITION BI 
EPN AND MALATHION ON I. V. ADMINISTRAT-
ION. ACH SUBSTRATE. 
Compound Do.e in 
mg/Kg 
Percent CbE inhibition (average value.) 
Cortex Medulla 
EPlf .3 ,30 $0 
5 50 14 
.. 
10 10 90 
20 100 100 
MalathioD 10 0 0 
50 10 0 
100 25 18 
200 50 38 
,300 60 51 
400 12 65 
55 
Death 
! 
0/5 Ii j 0/6 
II! 2/5 
,Iii 
2/2 i,l 
l 
I 
0/2 
Iii 
0/4 
0/6 ii',1 
1/:1 1/4 I 
3/3 
TABLE V 
DETERMINATION OF HOMOGENIZATION EFFECT 
-IF ANY- ON PERCENT INHIBITION OF CD 
EACH VAWE REPRESENTS AN AVERAGE VALUE 
OF THREE DOGS. ACH SUBSTRATE. 
56 
Brain tissue Peroent InhibitIon ot brain ObE 
Brain tissue treated 
wi th EPN (12 mg/Kg) 
1:1 ot brain tissue 
treated with EPN • 
brain tissue untreated 
homogeniaed together 
100 
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.$8 
or wnen compared to EPNJ its anticholinesterase ettect tirst 
appeared at a dose level of about 50 to 60 ms/Kg. Maximum 
inhibition of 65 to 70 percent was noticed with doses ot 400 mg 
/Kg. 
Cholinergic symptoms were also observed wIth 
lethal al well aa with effective dosea of Malathion. The aeverI~ 
t,. depended on how large a dose 'Vias given. Table 4 shows the 
relationship between brain CbE inhibition and lethality; it 
appeared that death did not occur until the do.e of about 400 mg 
/Kg ot Malathion in the ane8thetiz.d·~an1mal.. Aa atated, at that 
time residual activity of CbE wal still relatively high. 
2. In vivo interaction ot EPN and Malathion with brain 
CbEl 
-
To determine the degree ot irreversibility of the 
CbE inhibition produced br EPN and br Malathion in vivo, the 
dialyaia teohnique was used. Table 6 show. that the in vivo 
inhibition by EPN was not reversed by dial,..is, irre.pective ot 
dose. Similar type of irreversible interaction occurs in vivo 
between Malathion and CbE (Table 7). The.e re.ulta •• well u 
the data on irreversibility ot interaction between EPN and Mala-
thion in vitro indicate that the meaaurment ot the in vivo in-
hlbition is a faithful indioation ot the actual inhibition in 
the animal which was not reversed or modified by the prooedure. 
3. Eftects of BPN and Mllathion on true and pseudA CbE 
TABLE VI 
EFPECf OF DIALYSIS Olf THE III VIVO BPN' .. 
BRAIN CBE INHIBITION. ACH SUBSTRATE 
EACH VAIDE REPRESENTS AN AVERAGE VAWE 
OF THREE DOGS. 
Do.. ot EPN Brain Percent CbE inhibition 
mg/Kg Ti8.ue 
Cortex 
Medulla 
Oortex 
8 
Medulla 
Betore Atter Atter 
dialY8il: Z4 hours 72 hours 
d1al,81. d1a1Y8i. 
S3 
70 
68 
80 
70 
79 
So 
72 
66 
81 
59 
TABLE VII 
EFFEC'l' OF DIALYSIS ON THE IN VIVO MALATHIO. 
BRAIN OBE INHIBITION. AOH SUBSTRATE. 
EACH VAWE REPRESENTS AN AVERAGE VAWE OF 
THREE DOGS. 
Do.e of Brain Percent abE inhibition 
Malathion 
l1lg/Kg 
SO 
100 
tis8ue 
Oortex 
Cortex 
Medulla 
Betox-e 
dialysis 
11 
28 
17 
Aft.x-
.  
24 hour. 
dialysis 
10 
28 
IS 
Atter 
72 houri 
dialysi • 
8 
60 
61 
ot the blood. 
Three mg/Kg ot EPN vas glven I. V. to the whole anes-
thetlzed animal. An hour later, a blood s .. ple was wlthdrawn and 
analyzed tor 1t. plaaaa BuChE and RBC AcCnE actlylt1es, using 
Baoh and Ach substrate.. S1xty mg/Xg ot Malathion was injected 
similarly and blood activities ot abE'. were determined. The 
re.ult. ahown in table 8 indicate that EPN inhibited RBC enzyme 
more than plasma ChE, while Malathion inhibited plasma enzyme 
somewhat more than eo enzyme. 
4. Sins,e adminiltration in"jthe Mupper anyalft , 
The purpose ot the study of the "upper animal" waa 
to determine whether or not metaboli.m 1. nece.eary tor the 
activity ot EPN and Malathion &I well AI tor thelr potentlatlv. 
ettect to occur in vlvo. 
a. Intrajugular adm1ni.tratign. 
i. Non-incubated and Aiyer-ineubated EPI. 
Various dose. ot EPN were administered into 
the jugular vein in the "upper animal". Brain ti.8ue Wal then 
analyzed to determine it. ObE activity. The ettecte ot ElK on 
brain enzyme when given into the jugular vein to the ·upper 
animal" can be compared (Table 9) with. 1ts action when EPlf va. 
given 1nt' the temoral vein to the normal animal. It appeared 
that at a dose of 1.5 mg/Kg EPN produoed lome brain ChE inhlbitl0 
when injected into the normal aneethetized animal and had no 
TABLE VIII 
EFFECTS OF EPN' AID MALATHION ON TRUE 
A.ND PSEUDO ORE OF THE BLOOD IN VIVO. 
EACH VAWE REPRESENT AJl AVERAGE VAWE 
OF THREE ANIMALS. 
Do.. ot compound 
in ms/Kg 
Percent ot CnE inhibition 
RBO Pluma 
62 
eAch ,ub.trate)(Bzch .ubatrate) 
EPIi', 3 ms/Kg 
Malathion, 
60 mg/Kg 
6) 33 
32 
Do.e in 
lis/Kg 
10.0 
TABLE IX 
EFFBCTS OF BPN GIVD I. V. AliI) IftRA-
JUOCfLARLY TO NORMAL AND "UPPER" 
ANESTmID.'IZF.D ANIMALS RESPECTIVELY. 
EACH VAIlJE REPRF:SENTS AN AVERAGE VALUE 
OF FIVE At"lIHALS. ACH SUBSTRATE. 
Brain ObE activitr 
Oontrol = IOO 
6.3 
Given I.V. to normal 
ane.thetized animal 
Given intrajugularlr 
": to "upper anim~l" 
Non-incubated Incubated 
cortex Medulla Cort. 
90 116 100 110 92 129 
,30 10 100 100 12 So 
64 
.tt.ct wh.n injected into the ·upper animal·) 1a the latter 0 ... 
ErN did not oiroulate through the animal'. low.r part and 1ta 
viaceral organ.. At a dose ot 10 mg/lg EPN produced about 70 to 
90 peroent brain ebE tnhlbition when Injected into the normal 
animal, and bad again no ett •• t when given to the ·upper animal". 
From this oomparilon it ..... again that EPN had to be metabo-
lized, pre.umably in the liver, in order that it can ex.rt ita 
anticholinesterase ette.t in y1yo. 
To tind out more about this phenomenon other 
.erie. ot experiment. were carried oQt with variou. do.es ot 
liver-incubated EPN given via the jugular vein to the "upper 
animal". Five experiment. were carried out with a dose ot EPN 
ot 1.5 .g/Xg and 10 ms/Kg. Table 9 shows that tbe incubated EP. 
in a dose of 1.5 mg/Xg instead ot inhibiting, increa.ed brain 
CbE activity, particularly that ot the medulla. A Itatistlcal 
study has been done to asoertain the occurenoe ot thi. 
phenomenon. The EPN dose used in this oa.e was 1.0 ms/Kg. Tabl. 
10 shows the result. ot this analysis. The increa •• in brain 
CbE activity tound in this serie. ot 7 experiments vas stati.ti-
cally significant. 
11. won-incubated and llver-incubated Malathiona 
Experiments similar to the above were carri-
ed out wlth Malathion 1n the "upper animal". Non-incubated and 
liver-incubated Malathion was a4m1niatered into the jugular vein. 
The mean 
standard 
deviation 
95% CL. 
Brain ChE 
aotivity 
TABLE X 
STATISTICAL ANALYSIS OF MEDULLAR! CBE 
AO'fIVATIOll BY INtXfBATED EPN, IMG/KG 
ADMINISTERED IftRAJU OOLARLY. 
EACH VAWE REPRESEN'TS All AVERAGE OF 
TWO DEfERMINATIONS. ACH ~JBSTRATE. 
P1 of C~ ev01ve4/40 P1 of C~ ev01v84/40 
minutes O.g b~ain minutea 0 ag brain 
ti.aue (untreated) ti.aue (EP1f treated) 
., 
,32.25 4.3.20 
31 • .50 42.70 
32.25 41.50 
28.25 47.50 
,32.50 42.50 
.34.00 45.$0 
.34.00 46.50 
,32.10 45.50 
0.60 0.80 
,32.1± 1.4 45.5 ± 1.9 
lO~ 141.5~ 
ntH IS SIGNIFICAN'l' AT THE O.O~ LEVEL 
66 
Brain ti.sue was anallzed in each ca.e to determine it. CbE ao-
tivit1. Th. r.sults obtain •• (Table 11) indicate that Mala,hion. 
SO to 100 mg/Xg.had anticholine.tera.e actions when inject •• 
I.V. to the normal ane.thetize. animal. fbi •• ttect wa. more 
pronounced when non-incubated Malathion was given intrajugularly 
to the "upper animal" at the .ame d08e level in contradistinction 
to the relult. obtaine. with EPN. EYen at lower do.e level. 
(Table 11) Malathion inhibite. brain CbE when given intrajugular-
17 to the ·upper animal". Incubation with liver homogenate 
reduced anticholine.terase activitl bt Malathion, again contrar7 
to the result. obtained bJ EPN. Thus, liver metaboliam of 
Malathion ..... instrumental in the weak potencl ot Malathion as 
anticholine.tera.e agent when given I.V. to the normal ane.-
thetized animal. rinal17, unlike BPI, at do.e le •• l .. low a. 
10 mg/Kg and .. high al 100 mg/Kg Malathion did not produce 
activation ot CbE, onlf inhibition val ob.erve. with minimal 
ettective do •••• 
b. Intraventric91ar admini.tration •• 
i. Xon-incubate. and liver-incubate. EPN: 
The purpole ot u.ing this route of adminil-
tration vas to determine whether or not blood-brain barrier has 
anr ett.ct on ErN action. ErN incubated with liver and DPN al 
well as non-incubat.d EPN were injected into the brain ventricle 
ot the ·upper animal". Re.ult. obtaine. (Table 12) indicate that 
Do.e in 
mg/Xg 
10 
2.$ 
So 
100 
61 
'fABLE XI 
EEFECTS OF MALATHION GIVEN I. V. AND 
II'fRAJUOOLARLY TO NORMAL AND "UPPER" 
AIES'fHftIZED AlfDlALS RESPECTIVELY. 
EAOH VAUJE REPRESENTS AI' AVERAGE VAWE 
OF PIVE ANIMALS. ACH SUBSTRATE. 
Ptredet brain CbI 1Dhlb1tlon 
Given I.V. to normal 
anesthetlzed anlmal 
Glven Intrajugu~ar11 
to "upper an11lal" 
Bon-incubated Incubated 
Cortex Medulla Cort. Med. Cort. Med. 
o o 2 o o o 
o o 7 6 o 
8 o 2,$ 1,$ 12 o 
22 34 20 22 10 
TABLE XII 
I:FPEC'l'S ON' BRAII' CBE Bf EPN AIJ1INISTERED 
BI 'rH'REE DIFFEBDf ROOTES • .loa SUBSTRATB. 
EAOH VALUE REPRESENTS D AVERAGE OF THREE 
UIHALS. 
Boute ot Do.. 1n 
adm1niltrat1on mg/xg Brain ObE &ctlv1t7 Oontrol = 100 
Cortex Medulla 
68 
Non-ineub. Incub. Non-1ncub. In cub. 
Brain 
ventlticle 
eU • .1.) 
l!fnulU 
ve 
eU • .1.) 
Femoral 
vein 
(N.A. ) 
0.5 
10.0 
1.5 
1.5 
100 
100 
100 
90 
80 
69 
92 
U • .1. INDICATES "UPPER A..1'ifIMAL" 
N'... INDICATES NORMAL ANIMAL 
112 
100 
110 
116 
110 
52 
69 
non-inoubated ErN at a do.e of 10 .g/Kg produo.d no inhibition ot 
brain ebB when administer.d intrav.ntrioularly. It ahould be 
born In mind that thia do.e produced 70 to 90 percent inhibition 
ot brain CbB wnen admini.tered I.V. to nor.a1 anesthetized anlmal 
Liv.r-ineubated EPN in a do.e ot 0.5 .g/Kg given intraventrieul 
lJ produce. greater in.r .... ot CbB activity (Table 12) than that 
produced by 1ntra3ugulap admini.tration ot a do.e ot 0.$ ag/Xg. 
Larger do ••• of BPR produced brain CnE Inhibition (Table 12). 
provid.. liver-incubat.d EPN val employed. 
,..he.e data •• well as the rellult. obtaine. 
upon I.V. administration ot EPN to the ·upper aat.al" (ot. above, 
•• otion 4) ,ugse.t that BPH m.tabolis. 1. neoe •• ary tor 1ta ao-
tlvatloD a. an aDtloholine.tera.e rather than to lmprov-e' it. 
capacitJ to penetrate blood-brain barrier. Whether slven intra-
ventricularly or I.V. in the ·upper animal" ErN inhlbit. aore 
after incubation, paptio\1lulr in the tone. o .. e bloocl-braiD 
barrier .sa by-passe. and Jet the oompound inhibit.. ..pendiDg 
on It. activation in the 1lvor. 
11. Non-1g,uba,0. a.n4 liver-1goubated l!&atb1oas 
Liver-1Doubated Malathion and non-incubated 
Kalathion were a_inlstered bto the brain ventricle ot tbe 
"upper animal". EYen halt ot the d ••• ot Don-incubated Kalathion 
whicb was inefte.tive when admini.ter •• I.V. to tbe whole an~al 
inhibited brain CnE when adminlatered intraventrioularly iDto 
10 
the uupper animalu (Table 13). Here also as in the in vitro 
experimenta, liver incubation reduced the anticholinestera.e 
activity ot Malathion. ObE inhibition bJ non-inoubated Malathion 
given to tbe ·upper animal" va. almo.t equal quantitatively bJ 
both intrajugular and intraventricular rout •• , Malathion at 25 
m&/Kg produced 16 and 14 percent inhibition of cortical ObE 
wham given into the ventricle or via tbe jUgular route re.peetive 
lYe The •• data lugge.t that blood-brain barrier has no control 
over Malathion action. Allo tbe ettects were generally aimilar 
upon 1ntrajugular and 1ntraventriculera4m1nistratlon& ot liver-
inoubated Malathion. However, the choice ot the rout •• eemed 
to influence the distribution ot Malathion. When given intr-
ventricularlJ, Malathion inhibited medullary enzyme more than 
the cortieal enz1lle vhile when administered I.V. ato either 
normal or uupper anlmalu it inbibited cortioal more than the 
medullary enzyme. Tb11 dependance on the route ot .eleotivity 
ot aetion ot Malathion toward ObE of ditterent parts of tbe brain 
il not under.tood (ct. Discul.ion). 
5. T1!e·ertegt relationship or small do... of ErR and 
ot Ha,atb&oQ. I4Ilni,t!red *&~.f 
The indication obtained above that EPN siven via 
intraJugular and intraventricular routel cause~ at low dOle level 
inereaae in CbE a.otivlty urged more careful study ot EPN errect 
given by the I.V. route in normal anesthetized animal. Similar 
Route ot 
TABLE XIXI 
EFFEC'l'S ON BRAIN CRE BY MALATHION 
ADMDfIS'l'ERED BI THREE DIFFERENT ROUTES 
EACH VA-WE REPRESENTS AN AVERAGE VAWB 
OF THREE ANIMALS • .lOll SUBSTRATE. 
Do.e in Percent CbE inhibItion 
adminI.tratlon Jlg/Xg 
Brain 
ventricle 
(U .A.) 
Jugular 
vea 
(U • .1.) 
Femoral 
veln (N.A.) 
Cortez 
lfon-incub.!Incub. 
25 16 10 
25 14 7 
SO as 12 
50 8 
U • .1. IIDICATES "O'PPER ANIMAL" 
N.A. INDICATES NORKAL ANIMAL 
Medulla 
lfon-incub. 
28 
9 
15 
0 
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Irlcub. 
16 
0 
0 
12 
atudy was alao carried out in the ca •• ot Malathion. 
a. Time-etteot ,elatlonahiE ot ElB, 
EPK in a dO.8 ot 2. mg/Kg waa given I.V. to tne 
normal anesthetized an1mal. At difterent lengtb.a ot t1me atter 
tne injeotion tne ant.al was sacrified and the brain was analyzed 
tor ita OnE aotivity. It appeared (Table 14) that EPW in .mall 
rrle d L<.ll uX' I: 
do.e. increa.ed tne activity 01' brain dhB. The inore •• e reached 
" 
its peak at 40 minutes, return to control or slight inhibition 
tollowed. The.e results were in agre.ment with those obtained 
with .... 11 dos.s ot EP. adminiatered,!into the "upper animal". 
b. Time-etteot relatiogshi, 91' Malathion, 
Malathion in a d~.e ot 10 to 100 .g/Ig waa given 
I.V. to normal anesthe\lzed dog.. An1mala were aacritied atter 
ditterent t1me intervals. and brain CbE activity wal determined. 
With emall do.e. ot Malathion (10 to 25 ms/lg) there Wal no 
increase in ObE activity in the brain. alight inhibition occured 
with larger dose (Table 15). It could be caloulated from the 
dose-etteot relation.hip ot EPlf and Malathion that 1 .g/Kg doa. 
01' the tormer whicb. aa seen activated the enz,.., was equi-
ettective with 45 mg/lg doee ot the latter which was inettecti.e 
or eamvbat inhibitory. Whenever Malathion cauaea inhibition it 
was nearly constant tor more than two hours. 
c. :sttects ot EPlf and 01' Malathion on braip p,eydo 
.!&II 
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TABLE XIV 
Tnm",D'P'1JtO'l' DLA'l'IODKIP Olf BIUI CBE 
OF :2. MG{XG OF BP:r GIVD I. V. TO NORMAL 
AN'ESTBEflZED ANIMAL. ACH AND BZClI SUBSTRATE. 
EACH VAWB REPUSElfl'S AN AVERAGE VAWE 
OF THREE ANIKALS. 
'l'1IIe at which 
wain lamples 
w.e taken 
attap the 
injection 
20 minute. 
40 mInutes 
75 .!.nut •• 
150 mInute. 
Cortical actlvItr 
Control = 100 
AcChB BuChE 
95 85 
75 85 
60 70 
75 
Hedullarr activIt1 
Control = 100 
AoCbE BuChE 
12) 125 
131 140 
112 106 
84 90 
TABLE "X)I 
TIME-EFFECT RELATIOlfSHIP ON' BRAIB CHI OF 
100 MGIKG OF MALATHION GIVBI I.V. TO 
B'Omw, ANBSTRJJ:rIZED ANIMAL. 
EACH VALUE IS AN AVERAGE VAmE 01' THREE 
AlfIMALS • .lOa: AND BZCa: SUBSTRATES. 
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Time at whioh 
brain .ampl •• 
we".. taken 
att •• the 
inje.tion 
Cortleal inhibItion Medullary InhibItion 
A.ahE AcObB BuCn:i 
20 minute. 22 40 o 
40 Ddnutea 39 o 
90 minute. 22 37 o 
7S 
TEds was studied in the course ot the investi-
gations on EPl( and Malathion time-ettect relationshlp. Table ~ 
indicates that EPN at small doses activates and at large doaes 
inaotivates medullary brain pseudo CbB in parall.l with its 
actioil upon brain AcChE. In the cue ot Malathion there was only 
inhibition ot pseudo CbE (BuChE) as well as ot AcOhE (Table 15). 
In other words ettects ot EPN and Malathion on BuChE were always 
analogical to those on AoCbE. whether in caae ot inhibition as 
with EPN and Malathion or activation, as in the cue ot EP!l alone. 
B. Combined administrationt. 
1. I.V. rout.: 
1'h1s study' was carried out to analyze the eftects ot 
combination ot EPl( and Malathion on brain ehE. EPI' wu adminis-
tered I.V. to animals in ditterent d08ea ranging from 1 to 10 mg 
/tCg. Omt halt hoUl' later, Malathion wu administered in doses 
ranging trom 10 to 50 mg/Kg. Brain tissue was analyzed for 0hE 
activity. Tabl. 16 shows pereent brain 0hE inhibition and the 
death frequenoy with ditterent combined dose8 ot EPI and 
Malathion. To deaoribe more .peoifically the phenomenon ooouriag 
with one dOS8 combination, the toxicologioal and enzymio ettects 
at admin1stration ot 2 mg/Xg ot EPIl and 10 mg/Kg ot :Malathion 
will be described. Death ocoured within 10 minute. atter the 
injection of the seoond oompound (Malathion) in about 85 peroent 
of the treated animals, it waa preoeded by cholinergio symptoms 
TABLE XVI 
III VIVO IlfHIBI'1'ION OF BRAIN CBE UPON 
COMBINED ADHINISTRATION OF DIFFERENT 
SEQUEIiCES AND OF DIFFERENT DOSAGE RATIOS 
OF EPN AND MALATHION'. ACH SUBSTRATE 
Do. e in mg/Kg Sequence ot Percent ebE inhibition 
administration (Average valu.e.) 
Medu.lla cortex 
., 
BP:tr 1 ms EPN prior to 50 80 
JIalathioD So 118 Malatb.1on 
EPK 2 m, BP:tr prior to 85 6S 
Malathion 10 ms Malathion 
EPN 2 mg EPlf aDd Malathion 18 8 
Malathion 10 JIll .1111.11 tarutoua ly 
EPlf 2 m8 Malathion 10 0 
Halatb.1on 10 ms prior to BPI 
EPN 10 mg Malathion prior 80 100 
Malathioll SO JIlS to .,If 
EPN .$ mS Malathion prior 69 68 
Malathion SO m8 to EPH 
EPlf 3 mg M&latb.1on prior 62 68 
Malatb.1on 60 ag to EPN' 
16 
Death 
ratio 
414 
40 min 
5/6 
10 min 
0/3 
0/1 
2/2 
30 min 
2/2 
40 min 
4/4 60 min 
i,l 
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already described. Brain ObE inhibition was about 85 percent in 
tne medulla and about 65 peroent in the oortex (Fig. 12). In all 
those ea ... the blood ObE inhibition waa alwAJs complete while 
brain enzyme inhibition was not. 
A .imple algebraic equation was used (Table 17) to 
ascertain whether this extent ot inhibition was due to additive 
aotion or to potentiation. The equation allowed the calculation 
ot the oombined AED50 tor both compound. (AED50 is the .v~age 
ette.tive dose producing So percent inhibition ot ObE) as well 
a. tor their oombination.. It appe&p. that a potenti.tive 
inhibition .ocured sinee the combined AEDSO was much higher when 
caloulated (91 mslKg) than when me.sured (51 ms/Kg, Table 17). 
2. the etteet ot various sesuen •• , on ooabtged I.V, 
a .. inia'rati!D. 
Sinoe potentiation oooured when EPN vaa administered 
prior to Malathion the ~estion ari.e. as to whether or not 
potentiation would al.o occur it the •• quen.e ot the combined 
administration i. rever •• d. To answer thi. question tour 
experimental .eri.. were carried out. 
a. ZP., 2 .allg, waa administered I.V. )0 minute. 
~ 10 mslXg ot Malathion 
b. EPN, 2 as/Xg, was admini.tered .1mu1taneou.1I 
with 10 ms/Kg ot Malathion. 
o. EPN, 10 mg/Kg was admini.tered I.V. 50 minute. 
atter Malathion, So mslXg 
100 ~--------------------_ 
% INHlalTlON 
OF ACHI 
eo 
10 
40 
20 
o 
CORTEX 
I 
IPN MALATHION +EPN 
MALATHION 
FI(JJRE 12 
MEDULLA 
I 
l 
E~N MALATHION '~N 
+ 
ttULAlHlON 
EFFEO'1' ON BRAIN CHE BY COMBINATION OF COMPOUNDS 
GIVEN I. V. TO THE NORMAL ANESTHE'fIZED ANIMAL 
(EPN_ 2 MG/ltG GIVEN PRIOR TO MALATHIO., 10 KG/KG) 
EACH VAWE REPRESENTS AN AVERAGE OF FIVE DOGS. 
AeB SUBSTRATE. 
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TABLE XVII 
MEASURED Alm CALCULATED AEDr;o IN MG/XG 
OF COMBINED EPN AND MALATHION. 
BlOH VAWB RRPRESEl'fS Alf AVERAGE VAWB 
OF SIX ANIMALS. .lCB SUBSTRATE. 
Cortex 
AEDso combined in 
.g/xg 
Meuured 
51 
caloulated trom 
tb.. equation 
91.8 
TIm E'3JATION': 
I 
PBRCENT, RATIO EPN 
IN OOMBINATION 
---------------+ 
PERCENT RATIO. MALATllION 
Dr OOHBlKATIOlf 
19 
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d. EPN, lms/Kg was admlnlstered $0 to 120 mlnut •• 
I.V., Itter Malathlon, 60 mg/Xg. 
The r.sults ot those experiments are shown 1n 
Fig. 1.3 and Table 16 and can be sWJUll81"ized as tollows: 
i. Cholinergio symptoms developed in all s.rie. 
ot experlment •• 
11. Potentlation ot brain OhE inhIbition ocourea 
in (e) and in (d) but not in .eries (a) and (b), 1.e .nen EPN, 
2 mg/lg was glven simultaneous ely with or atter Malathion, 
10 mg/Ig. ill. Lethality occured again in .eries (0) and 
(d) but Dot in .erle. Ca) and Cb). The tact that potentiation 
ot toxicity and ot brain ObE inhlbltlon did not occur in .eri •• 
ea) and (b) does not necessarily .ignify that the dose ot 
Malathion in question (10 nag/Kg) was a •• troJed in the llver 
wlthout havlng the chance ot being protected by EPN .ine. 
Malathion at this particular dose glven Intrajugularly to the 
·upper animal" and thus not a •• troyed by the liver, did not 
produce a .ignifioant brain CbE inhlbition. 
ly. When ErN, 10 l'Ig/Xg Val giYen Itts Malathi_ 
( •• 1'1 •• 0) lethal1t1 maJ be due to toxio ettect ot EPN sinee at 
thi. dose it .om.times produce. death. BoweYer thi. does not 
seem to be the only caus. ot death .inee potentiation ot both 
lethality and the enzyme inhibition oocur.d al.o when minlmal 
ettective dose ot EPN (.3 mg/Xg) was given prior to minimal 
%INHIBITII~ 
OF ACHE 
80 
60 
40 
20 
CORTEX 
I 
I 
I 
I 
I 
I 
I 
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MEDULLA 
u ~--~~~~-~I~----~I~------~:~~ ____ L-______ ~ ______ ~ 
MAlATHION. EPN,I/2 HR. EPN, MALATHION, EPN,I/2 HR. 
AFTER 
MALATHION 
il2HR, AFTER AFTER MIXED WITH I/2HR.AFTER 
EPN MALATHION MALATHION EPN 
FlGUU 13 
EPN. 
MIXED WITH 
MALATHION 
EPFEO! OF THREE DIFFERENT SB!CPENCES OF COMBINED 
ADMINISTRATION OF EPlf, 2 MG/XG AND MALATHION, 
10 HG/XG. EACH VAmE REPRESENTS AN AVERAGE OF 
THREE Dlfi'ERMINA.TIONS FROM THREE DOGS. 
AOR SO''BSTRATE. 
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ettective d08~*)(60 mg/Eg) ot Malatbion. 
y. In •• rie. (d) in .pite of the tact that deatl 
and potentiation of brain ObE inhibition occured the latte~ was 
not .s extenlive aa when EPN Val given prior to Malathion, 
potentiation ot inhIbition .. ounted to 20 to )0 pereent above 
value. expeoted on the ba.i. of pure addition. 
vI; In serl •• (d) in which MalatnioD was given 
prior to EPN death occured within 60 minutes of the administra-
tion ot the .eoond compound (EPN) while when EPN waa given prior 
" 
to Malathion death occured at on17 1'to 10 minute. atter the 
administration of the •• cond compound (Malathion). 
Th. blochemieal data obtained in this s erie. 
of experiments agree fair17 well with the pharmacological data 
obtained in the same laboratory, aince potentiation ot pharmaco-
dJUamic etfects was noticed in a study ot action. of EPN and 
Malathion at specific neuroettector.. For instance, Malathion 
28 .g/Kg given 45 minutes prior to EPN. 2.5 mg/Kg, produced 
inoreaa. ot ronacle re.ponse to indirect stimulation while 
IJIalathlon and EPU given singl,-, produoed increased muacle twitch.e 
at dOl •• of more than 2$0 and 12 mg/Xg respectively (Kaczmar. 
Awad and Blachut, unpublished). 
(*) fhe m1D1mum effective do.e i. the smallest do.e capable of 
producing significant (~15 percent) inhibition. 
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3. Combined a.clm1nistration to the Ifupper an1Jaa~" t 
a. Intrajugu*~f 
i. Non-incubated c9!R0und.: 
In the ·upper animal" lPN, 0.5 to 2.0 mg/Kg 
W&I admini.tered into the jugula.r vein )0 minute. prior to 
Malathion, 10 to 2$ mg/Kg. The results obtained (Fig. 14) 
indioate that non-incubated combined EPN and Malathion did not 
produce potentiation at )0 minutes in the ·upper animal lf atter 
the admini.tration of the second compound. However at 60 minut.s 
after their administration potentiation ot brain CbE inhibition 
developed, particularly in the cortez. 
il. Liver-incubated cO!Poundl' 
!PH ... incubated with liver and DPN and 
administered via the jugulat- vein to the "upper animal" 30 
minutes prior to administration of incubated Malath1on. The 
result, obta1ned (Table 18) ind1cate that potentiation ot abE 
Inhibition was produced )0 minute, after the adm1nistration ot 
the second compound. 
Potentiation occured alao htom combination 
ot incubated EPB and non-incubate. Malathion (Table 19). In 
this experiment conditions tor de.truction ot Malathion were not 
pre.ent, aince Malathion was administered without liv8r and 
8inee EPN concentration was .eleoted 80 a8 to de. troy ~ala­
thion .. e" of it. own liver medium. Thus, potentiation in thi. 
IOOr-----------______________________________ ___ 
o 
% IN HI SITION 
OF ACHE 
100 
o 
Six T Y ~INUTES AFTER DRUG ADMINISTRATION 
CORTFX MEDULLA 
I --L -------________ --'------_---.Ji~ __ l _ _ _ 
EPN MALATHI~ EPN EPN MALATHION (PN 
+ + 
MALATHION MALATHION 
IIIINETY MINUTES AFTER DRUG ADMINISTRATION 
-. 
CORTEX MEGULLA 
I I '---:E::P=N--:-M:-AL-ATH=,O-N---Lf'-:-~----------------L--~ i ---- ! ---
EPN MALATHION EPN 
+ + 
MALATHION MALATHION 
FIGURE 14 
EFFECT ON BRAIN CBE OF COMBINATION OF NON-
INCUBATED COMPOUNDS GIVEN INTRAJUOOLARLY TO 
THE "UPPER ANIMAL" AT 60 AIm 90 MINUTES AF'l'ER 
THEIR ADMINISTRATION (EPN, 2 MG/KG GIVEN )0 
MIllTTES PRIOR TO MALATHION', 10 MG/KG). 
EAOH VAWE REPRESENTS AN AVERAGE OF FIVE 
DE'l'ERMINATION'S FROM FIVE DOGS. ACH SUBSTRATE. 
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Compound 
'fABLE XVIII 
EFPEC'l' Oll' IN'l'1U.JU (JJ LAi OOMBINED 
ADMINIS'1'RA'1'IOI OF Ell GIVEN HlLF 
BCXJR PRIOR 'f0 MALATlIION IHO 'fBB 
"UPPER ANIMAL" • .lOB SUBSTRATE. 
BAOH VAWE REPRESENTS AN AVERAGE 
VA-WE OF THREE ANIMALS. 
Incubated 
85 
Bon-incubated 
Brain ebE actiY1tJ Brain abE act1v1ty 
control = 100 control = 100 
Cortu Medulla 
97 121 100 10.3 
Malathion ZS.O 94 100 86 93 
EPN prior to 0.5 
Malathion 25.0 
60 80 
TABLE XIX 
IftRAJO'GUUR EFFECT OF COMBINATION 
OF EPN GIVEN TO THE "UPPER ANIMAL" 
PRIOR TO 1l0lf-UCXTBATED MALA'l'HIOI'. 
BACH VAWE IS AN AVERAGE VAlIfE OF 
THREE dIMALS. ACH SUBSTRATE. 
Malathion, 
2S 
lIPll, 0.5 
Halathioa, 25 
Brain OhE activity 
oont1'ol = 100 
Oorta Xedulla 
97 121 
86 93 
64 
86 
87 
oaae could not depend on proteotion afforded bJ EPW to Malathion 
againat detoxification. 
b. IntraTentricular adminl,trat&o!!. 
1. NiP-intubate, qgmpounda. 
In tbe "upper animal" !PH, 0.05 mg/Kg, was 
injected into the brain ventricle 30 minute. prior to admini-
atration of Malathion, S ms/Kg. Tne re.ults (Table 20) .how 
that at 30 minut.. atter tne injection ot the leeond compound 
(EPN prior to Malathion) brain enzJ1De inhibItion wa. lOliewhat 
" 
greater than tba' expected on the baai. ot mere addItIve ettect •• 
Thil again sugge.ta that potentiation doe. not nece.sarily depend 
on protection ot Malathion by EPN. 
ii. LiTer-incubated eompount •• 
Ooncentration. ot ErN in the liver bomogenate 
were .elected with the precaution mentioned earlier (ct. p. 3). 
El. was incubated with liver in,pre.ence ot DPI and given tntra-
ventricularl,. to the "upper animal". 30 minute. prior to Ii ver-
incubate. Malathion. The result. obtained (Table 20) indicate 
that at 30 minute. atter the administration ot the .econd 
compound (Malathion) potentiation ot brain OnE inhibition 
'WIlier ... 
occured. Potentiation was much more pronounced than that~occur.d 
at 60 minute. atter combined intraventricular administration of 
the non-incubated compound •• 
CompoW'ld 
EPlf 
EPK prior to 
Malathion 
TABLE XX 
EPPECT OF INTRA VENTRIWLA.R ArtIINI-
STRATION '1'0 THE "UPPER ANIMAL" OF 
EPlf GIVD PRIOB TO MALATHION. 
EACH VAWE IS AN AVERAGE VAlUE OF 
THREE AlfIMALS • .leH SUBSTRATE. 
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Do.e 1n 
mr/Itg 
Incubated Non-lncubate4 
o.oS 
s.oo 
o.os 
.$.00 
Brain ObE aetivit1 Brain ObE activity 
oontrol = 100 oontrol = 100 
cortex Medulla 
llS 100 100 
96 92 
60 70 80 80 
O!IA.PTDl IV 
DlSroSSIOI' 
I. IaSridYlt'IB' 
Frawl.,. 1n 19S7 baa ahown that potentlatlen ot tbe aoute 
tOxiolty arla., tpo. almultaneous adminlatratlon of BPI and 
Malath.lon, lnh1bltlOD of blood ObE ... alao found to be more tbAn 
ad41tlv.. No tata we.e obtalAed with reterenoe to the erteet ot 
tbl. c.-binatlon on O.I.S. CbB. one of the purpoae, o~ tbe 
pre.ent studJ ... to •• tabll.n wheth •• or Dot lnb1bltlon ot braln 
CbE 18 al.. pot.ntlate4. 
Up to the p ..... t ,1m. 1t va. .qgeeted tbat tbe poten-
tlatlon pb.nomeDOD of ObE lDhlbltloD produoed bJ oo.blned 
admlnlstration of or,ano.pboaphorua antl.holln •• t ... a. oompounds 
1. due to the lnblbltlon bJ one ooapoW'ld of the de'onrloa'lon 
of tile otb.er (COOl: t I poatulate). WI til .e8&r4 to the \wo ooapound 
.tudled at ppe.ent, EPIJ and Malath.1on, Ooole (18) baa allow that 
lD vitro BPI' lobibS'e Malatb10n d.to:&1tl.at1_ bJ tb. 11 .... 
Tbe , ••• emt IJI,_.t10 atudJ ahows 1ft d.tall bow b.a1D 
ObE 18 atteoted bJ the oOllblnatlon of tboa. two oompound., hov 
their en.,.10 attect II lntluenced bJ tbeir 11vep metabolla., 
and wnatbep 01' Dot the ettect u.pon bFain .nzJ1I8 can ba conelatH 
with the tOxioltl of tn. combination. The •• data w111 b. now 
lweu-l •• 4 and oerta1n pointa atre.a" to show that vb.11. _OllIe 
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ot the ~esults supports Cook'. postulate others do not, accord-
ingly. an alternative h1Pothesis is pre.ented at the end ot this 
di.ou •• ion. 
i1. Surv.l ot the 19 vitro .tudies of IPN and Malathion. 
1. Single addition. 
In vitro studies showe. that EPN has weak anticholin-
e.terase action and that inoubation with liver homogenate and 
DP. l.ad. to the conversion ot EPN into a potent inhibitor ot 
ObB. fbis suggestl that in vivo ElN has to be metabolized, 
., 
probably in the liver, to,be ettective .. an antichollneatera.e 
asent, and contir.s earlier results on activation ot EPN by it. 
incubation with the liver (61). Incubation ot ErN with liver 
homogenate in absence ot DrN has shown no detbite incre .. e In 
It, antioholinesterase actlon. 
In vitro .tudl.. ot Malatbion ,howed that a relatively 
rapid d.er .... rather than incre ••• of anticholinester... ettect, 
tollowed it' inoubation with the 11ver nomogenate. Thi. agree. 
with the data obta1ned by Cook (19) showing that 1n vitro 
Malathion 1, inactivat.d with1n llalt hour ot incubatlon. 
Parathion, EPN and man7 other organopho.phorus compounds on the 
other band are Dot inactivated by the liver. Malathion ..... 
to be inactlvated .imilarly whether or not DrN vas added to the 
incubation medium. Thi. indicat.s that d •• truction of Malathion 
and activation of ErN are carri.d out by two difterent enzyme 
i 
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systems of the liver. 
2. Combined addition. 
Combined non-incubated EPN and Malathion producea in 
vitro inhibition ot brain ChE equivalent to the inhibition 
predictable on the baais ot an additive action. On the other 
hand cambination ot ElN and Malathion incubated with liver 
homogeDat. produce. potentiation ot their antioholinesterase 
ette.ts. Thi. agrees with the data of Bo.enberg (13) indicating 
tbat in vitro EPN and Malathion combination potentiate the 
., 
inhibition ot rat brain ChE only atter these compounds were 
incubated with liver. 
). Type ot interaction: 
In vitro stUdies have shown also that the interaction 
between ErN and Malathion with ebE are ot an irreverlible t1Pe. 
Moreover, when brain samples trom animals treated in vivo with 
EPN were added to and homogenized together with, brain aamples 
trom untreated animall, the enzrme ot the latter was not inhibi-
te. • This indicate. that no tree phosphonate compounds were 
pre.ent in the brain ot EPN treated anima18 and pre.umab1y not 
in the extra cellular Ipacel of the tilsues. However, tinal 
proot ot thia latter point depends on the use ot ditterent other 
techni.u.. • 
Tbis .et ot data Ihowa that the manometric •• thod can be 
reliably u.ed to .easure the inhibition in vivo linea the latter 
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could not be rever.ed in the course ot the preparation for 
analysis nor could th. actual inhibition be increased by the re-
le.s. of the fr.. compounds during homogenization. ~he7 a180 
show that there i8 at l •• st a cert.ain degr •• ot 8111ilaritl 
.. between EPI and Malathion both being irreversible inhibitors 
of ChE. 
III. Survez of the in v1vo studies ot the two compound., 
Systematic inv •• tigations have b.en carried out with 
regard to EPI and Malathion administered by various rout.s Singly 
or in combination to 4ne.thetl.ed animals. 
1. Sins,. a4!llJ1ltraticm' 
a. Eioch~1.a1 and toxic ette.t. of .ingle admini-
stration and relationship to toxicity. On I.V. admini.tration 
EPN was found to be & fa1rly potent antleholine.teraae agent. 
significant brain anz,.. inhibition begins with a do •• of about 
2 to 3 mg/.lg. Oholinergic SJMPtoms develop.d and its s.verity 
vas parallel to the cloaage glven. Death dld not oocur until 
about 90 percent lnntb1tlon ot normal activity of brain AcObE 
1) 
Val reoorded. 
On the othep hand Malathion given I.V. to anesthetIzed 
dogs vaa found to b. a rather veak brain anticholine.terase 
1) 
It Wal notic.d that EPN, S mg/Ig given I.V. to atropinIzed dogl 
d14 not produce bra1n OnE inhibition while it did 10 in non-
atropini.ed doge (riye animal. were used in each ca.e). Thi. 
might have a bearing on similarity between the enzyme and the 
central receptor sites surtaces. 
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agent, tnhibition began with a dose ot about 50 to 60 .g/Ig. The 
lethal d08e ot Malathion agreed tairly w.ll with that which 
produced toxicity of non-an.sth.tized dogs , and was tound to be 
about 400 mg/Kg. The severity ot cholinergio 8Jmptoma were a180 
papall.l to th. d08age giv.n, however, brain AcCnE inhihition at 
toxic level was about 60 to 70 percent, i.e. le88 than the 
inhibition produo.d br toxic d08 •• ot ElK. The level ot inhibl-
tion ot about 90 p.roent characterlstic tor the lethal d08.. ot 
!PH is in 010 •• agr •••• nt with the relults ot Metz (62) who 
produced re.piratory tailure with TEP-P at 90 perc.nt inhibition 
levels .t •• dull&r1 A.abE. In ease ot TEPP as probably allo in 
that ot BPI' death can be attributed m08tl1 to inhibition of brain 
AcOhE or more .peoifically to that of medullary AcOnE whicb i. 
higher than that ot the cortical enz,..e. on the other hand CbE 
inhibition by Malathion was lower at deatb thaD that which 
obtained not on11 with lethal doses ot !PN but also wi,h l.thal 
dose. ot .everal other organopho.phorus compound.. Malathion 
toxicit1 .e... theretor. to b. due to a combination ot brain 
enzyme inhibition and other faotors. The taotors that m«1 be 
involved are as followa. 
i. Peripheral CbE inhibition~ At 10 peroent inhibi-
tion ot C ••• S. CbE the enzyme ot the li.M.J. and ot the ganglia 
may be compl.tlr Inhibited; in tact, tn the cue ot Malathion 
blood CbE ls coapletly inhibited when C.NeS. enzrme is only 70 
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percent inhiblted, while wlth EPN central and peripheral cholln-
elterase inhibltion mal run parallel. The importance of this 
taetor cannot be aleertained, since the activlty of ChE in the 
tis3ues 
peripheral- other than in the blood- hal not been determlned in 
the present Inve,tigation. 
11. Non-cnolin.,teraaic tactors lueh as dlreet 
neuronal tOxicity central or perlpheral or both. Actually, 
central toxic6tl of Malathlon mal depend on a conditlon of direct 
neuronal tOxicltl and of central CbE inhibltlon • 
. , 
In tact, the data obtained wlth regard to Malathi-
on toxicltl mlght agree wlth Frawley data (33) indicatlng that In 
the caae of certain organopho,phonate. convulalve do ••• produe. 
relatlvell 11ttle central ensymlc inhlbition. ~h. alertlng 
ettecta ot ElK and Malathion upon the cat BEG as well aa thelr 
antagoniam of atroplne ERG, studled in thla laboratory (7) are 
ot inter.at in thil context. The ettectlve doae ia 8 mg/Xg and 
250 ms/Kg tor EPN and Malathion reap.cti •• ly (7), actuallt 
alertlng lometim.. could not be obtained with &Dl dose of Malathi-
on. Tbi. i. in agree.ent wlth the tact that the lethal dOle of 
Malathion dld not inhibit brain AeOnE abo •• 70 percent level. 
Thi. may allo lugge.t that of the two pOI.ib111tle. mentioned 
above ot 8ither central non-eholinesteraale faetora or of 
peripheral probabll cholin.aterasie factors as cODt~lbuting at 
Malathion toxicity the latter ahould be consldered partlcularly. 
9S 
b. Role ot metaboli.m. Metaboli.m ot BPI and Malathion 
artecta their antloholine.terase aot!vit!e.. Thi. was shown by 
the difterence in potency ot their In vitro and in vivo anti-
choline.ter .. e action.. EPB vas a weak Inhlbltor in vitro (Iso 
= 2.>< 10 -~) but a potent inhlbitor in vlvo, vhile Malathion was 
tairly potent inhlbitor in vitro (I.$O = 0.8x lO-.5M) and rather 
w.ak Inhibltor in vivo. The ettect ot metabolism is also indi-
cated by the ditterenoe betw.en antlcnolinestera.e potency ot 
the non-incubated and ot 11ver-incubate. compounds admini.tered 
to the "upper animal· intrajugularly!or intraventricularl,.. In 
thi. o .. e EPli, 10 JIg/Kg, did not attect brain ObE when admini.ter-
ed via either POute witnout previous incubation, while it cau.ed 
signitioant Inhibitlon when given by either route atter liver-
inoubation, 1I0reover wnen thi. do.e ot EPN (10 Ills/Kg) is admini-
stered I.V. to the normal animal and thus metabolised (activated) 
In vivo 90 peroent inhlbltion ot brain AeOnE r.sults. 
Non-incubated Malathion adminlstered intrajugularly 
to the "upper anbal· aigniticantly inhiblted brain ObE at the 
doa.. of 2.$ to So mg/Eg, and only by halt as muoh after inouba-
tion with 11ver homogenate. The same do ••• wnen glven I.V. to the 
normal an •• thetized anlmal inhibited ObE very slightly. 
e. Ditterential aftinltie.. Inter.stingly enougn, 
Malathion and ErN •• e.ed to exhlblt dltterentlal aftinitle. to 
varlous are.. ot the brain. Independently ot tne route ot admini-
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.tration EPN always inhibited the medullary more than the co~ic-
al enzyme, Malathion on tne otner band sbowed more atfinity to 
oortioal than to medullary enzyme wnen adminietered to the normal 
a 
animal or 1ntrjugularly rothe "upper animal". However, when 
Malathion vae &'-inietaraa intraventricularl" it inhibited the 
medullvy enzyme more than the oortioal one. 
Compounds admini.tered I.V. are generally expected 
to na •• more &c,o •• s to medulla tban to OOl't_. Ttle explanation 
tor this being as tollowa. The tvo onorlo1d plexl in tbe brain 
enolo •• the torth ventricle 010 •• to~me4ull&l"1 area and the 
lateral v.nt~cl •• in the neighborhood ot the cortex (Fig. lS). 
As Inter.t1tlal fluld. and oompounds oapabl. ot orosslng blood-
brain barrier- pa •• t%l'om the blood to brain ventriol •• through 
the ohriold plexl and a. the tluld In the lateral v80trlol.. 1, 
conv8J" down to the tour-th ventricle, the IIMu11. should have 
the chanee of abaorbing oOlllpound. both. trOll the chorioid plexu.a 
1n its vio!n!t,. and trOll the tluld dueending UPOll it trOll the 
lat.ral ventriolea. On the other han. on intraventricular 
admlnlats-atlon into the 1a, ... 1 ventr101.. the oortex would be 
the near •• t to the depot ot the drug and more likely to be 
attected by their actloas. Obvlou81,. th ••• topographical factor. 
did not oontro1 the di.trlbut1on or EPN and l(alathion alnoe the 
medulla vas the 81 te ot EPN aetion uPOD lntraventl'loular adminl-
stratlon whlle oortex Was mOltly afrected when Malathion was 
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given I.V. Other factors must be involved. 
d. Dual action ot !PH. Anotner interesting observation 
was that EPN had two actions upon brain OnE depending on ita 
dose. In do.e ... amall aa 1 to 2 m£/Xs given I.V. to tne 
normal ane.thetized animal or given via the jugular or the 
ventricular route to the "upper animal" EPN .ignificantly !n-
creased its activity. When EPH vas given I.V. in thea. do.e. 
to normal anesthetized animal the increase in activity ot brain 
ebE reaohed a maximum at 40 minutes and was followed by return to 
control level or by slight inhibition. Malathion on the other 
hand did not inorease the activity of brain .nsrme at any .ub-
inhibitory dose level tried (10 to 100 mg/Xg). 
e. Effect on brain pseudo ChE. The action of EPN and 
Malathion tovards brain pleudo CbE should be also mentioned. It 
haa been found that their aotion on pseudo CbE vaa parallel to 
that on AeOhE. In the oas. ot EPN both activation and inhibItion 
occured in parallel with regard to true and to pseudo brain ChE. 
It is to be borne in mind that ~he amount ot p.eudo OhE pre.ent 
in the braIn is small and that thererore its inhIbition might be 
expeoted not to be of great importance. However De.medt (22) 
claimed that toxicity ot organophosphorus oompounds is due to 
inhibition of pseudo OhE rather than to that of AcOhE. Thi. 
conclusion can be criticized because most of the compounds ueed 
by Deemedt could only poorelf penetrate through blood-brain 
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bar~l.r (Rol.atedt, 43). 
t. Role ot C.N.!. barrier. Non-incubated EPN, 10 mg/Kg 
did not produce any .ttect on bpaln AcChE when given Yia the 
ventricular pout. to the "uppep animal". At 20 mg/Kg. non-incu-
bated F.PN produced sOl'IIe inhibition ot tile anz,... when given intpa-
jugularl, to the "upper animal". This lndicate. that blood-brain 
barrier dld not prevent the non-incubated (not actlYated) !PH 
from reaching the brain, and that the Inhibitlon obtainea upon 
I.V. adalnlatl'atlon was that which could b. expected on tne buia 
ot quantltatlve penetration ot non-lncubated EPN into the brain. 
It se... than that whl1e metabolla. ot EPN Inol'e ... o It. Inhlbl-
tOPJ potanc7 ainee at a do.. ot level ot 10 mslRs only the 
Incubated compound inhibited brain ebE regard Ie.. ot the pout. 
u.ed, activation waa not required top making It absorbable via 
tbe blood-bnln b8l'l'1er. Inotnet" worda lIetabolia. or EPN 
Inor..... Ita capability ot attacking the brain eDara. at the 
cell alte. 
Non-inoubated Malathion inhiblted brain ChE vbetbel' 
admlnlatered via the jugular veln or Into the vent~lcle or the 
"upper anllUl. It. Thia .howa a.1lo that Malatb.Iem penetration to 
the ventriole Ie not oontpoled bJ the blood-bra1n bar:t-ler. The 
reductIon In 1nh.lbltlon was eimllar when liver-incubated Mala-
thion was admlnlatered via .1ther route. Thia indicat.a tbat 
metabolla. do •• not alter Malathion penetra_l11ty through the 
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blood-brain barrier. 
2. Oombined administration • 
• 
a. Eftects due to EPN given 30 minutes prior to Malathia 
While inhibition ot brain OnE atter EPN-Malathion combination 
vas Independently ot the dose. ot the two compounds always much 
higher than the inhibitIon Which would result from additive 
ettect ot both compounds. certain other results ot the combined 
administration to anesthetized dogs depend on the dosage ot the 
two components ot the combination. When the doaes ot EPN and ot 
Malathion were 2 and 10 mg/Kg respectively 8S percent ot animals 
dIed. Death occured within 10 mInutes and InhIbItion ot brain 
ObE va. greater in the medulla (BS percent) than in the cortez. 
On the other hand, when EPK and Malathion doses were 1 and So 
mg/Kg respectively d •• th occurea within 40 minute. and cortical 
enz,..e va. inhibited more than the medullary enzyme. 'fb.1. 
indicates that larger the ElN traction in the combined ao.ini-
stration the taster death occured and the more inhibited va. 
medullary ebE. To the contrary, when EPN dose was lowered and 
Malathion dose increased death occured slowly and the cortical 
enzyme was inhibited more than the medullary one. Thul as either 
Malathion or EPN content ot the combination is increased, 
inhibition at the site characteristio tor the pertinent compound 
i. tound to predominate. Thua in the case ot 2 and 10 mg/Kg 
EPN-Malathion oombination medullary enzyme was inhibited by 8S 
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percent wb11e in the ease ot 1 and So ms/Kg combination the 
inhibition was only SO percent yet .eath occure. in both .erie •• 
Thi. again 1. another evidence indicating that Malathion toxicity 
1. not entirely due to brain CbE inhibition. The data maJ a18. 
suggest tbat Malathion even when admini.tered ,30 minute. atter 
EPN .eem. to prevent EPN from exerting its full actlon at the 
medullary slte. 
1. Role ot metaboliam. In the "upper animal" 
combined Intrajugular or intraventricular administration ot non-
inoubate. EPN and Malathion produced:atter a characteristic 
.elay (60 minute. atter the administration ot the .econd compound j 
potentiation ot the brain ObE inhibition. Potentiation ot 
inhibition vaa particularly pronounced in the cortex. When the.e 
compound. were similarly admini.tered atter inoubation with liver 
homogenate potentlation ot brain CbE inhibition was produced 
taster <at ,30 minutes atter the adminlstration ot the .econd 
compound), to a greater extent, and It occurea in the cortex an. 
in the medulla. Again, the inhibitory etrect was potentlativ. 
rather than additive. 
li. Role ot O.N.S. barrier. When EPN, Malathion or 
0-
their combinatioDS upon Intr.!entricule administration do not 
inhiblt at certain dose levels unle.. incubated, this naturally 
.eans that the metabolism ia nec •• sary tor aotivation and in-
creaae ot inhibltory action aince blood-brain barrier doe. not 
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matter in the ea.. of this route) on the other band, lack of CbE 
inhibition upon intrajugular administration unle.s incubated of 
single compound. or ot their combination. may mean that 1ncubatio~ 
ie needed both tor activation and penetration acro.. the blood-
brain baprier. 
The pre.ent data obtained from combined admini-
Itration of EPN and Malathion indicate that .etabolism is oece.-
lary for taater and for more pronounced inhibitory potentiation. 
Combination ot liver-incubate. compounds produ.ed potentlation ot 
brain ebE inhibition in both cort.x and ~e.ulla, at 30 minut •• 
atter the administration ot the •• cond compound, while with non-
incubat.d compound. potentiation of the enzyme inhibition ari •• s 
to a l •••• r extent and not until 60 minut.s att.r Malathion 
administration, thi. latter potentiation occur.. only in the 
cortex. Similar degree of potentiation occured on intrajugular 
and intraventricular administration to tbe "upper animal-. ~his 
indioate. that blood-brain barrier doe. not affect the penetration 
of thOle compounds into the brain. 
iii. aelationship to toxicity_ Sin.e metaboli •• 
(activation) of ErN incre.sed tbe pot.ntiative and anticholin-
ester ... aotivity in the 0.N.8., the potenttation of toxicity 
with regard to combined admini.tration of EPN and Malathion could 
be at le.at partly related to brain AcOnE inhibition. It high 
enough the latter could oau.. death directly or bping about 
secondary tactors auch as cardiovascular disturbance which in 
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turn may oontribute to toxioity. However peripheral CbE inhibi-
tion at sites such as N.M.J. are very likely to contribute to 
the potentiation of toxicity arising on combined administration, 
since such factors .eem to contribute to the toxicity of Malathlo! 
whon given singly. 
The bioohemical data obtained in the present 
study agree with the pharmacological data, In this laboratory 
it has been shown that good antagonism of atropine EEG and 
marked alerting as well al convulsive REG pattern relulted from 
combined administration ot EPN, 2 to~4 ms/Kg and Malathion, 8 to 
12 mg/Xg (unpublished). In this cas. the neuropharmaoological 
data could be correlated with the inhibition of brain CbE. On 
the other hand, pharmacologically the potentiation was not 
confined to the C.N.S. and eould be ob.erved a180 at peripheral 
neuroettectors such a. neuromyal junction and at the ganglia 
(Karommar, Awad and Blaohut, unpublished). Also aa mentioned 
earlier the present data showed that in the case ot combinationa 
with a relatively high content of Malath10n the extent ot central 
CbE inhibition at toxic dos •• is rather low. The above results 
suggest that both peripheral and central sites may be involved 
in bioohemical and pharmacological potentiation and also in the 
potentiation of toxicity. Also, direct neuronal toxicity cannot 
be excluded. 
b. Effeeta arising from varying the sequenoe of EPN and 
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Malathion administration. The potentiation ot brain ChE inhibi-
tion d.scribe~ above was obtained when EPN was administered 
prior to Malathion. The question then arises whether or not 
potentiation ot OhE inhibition would also occur it the sequence 
ot administration ot Malathion and EPN were reversed. As will 
be seen this has a bearing on the mechanism involved in poten-
tiation • 
Studies were carried out with Malathion, 10 mg/Kg 
administered prior to or simultaneously with lPN, 2 mg/Kg • 
. , 
While CbE inhibition occurred there was no death nor potentiation 
ot inhIbition, although distinct cholinergic aymptoms and toxici-
ty aroa8. The medullary ChE inhibition arising trom the above 
oombination leemed to be le.s than that produced by similar 
doses ot EPN given singly, suggeating that Malathion prevents 
tull anticholinesterase .ttect ot EPN trom being exerted. 
Similar interpretation can be applied to the tact that when 
Malathion was given 30 minutes atter EPN medullary CbE reached 
8S percent level with 10 mglKg dos8 ot Malathion but va. only 
50 percent when Malathion dose in thil combination waa increased 
to So mglXg. 
It should be remembered that the dos8 ot Malathion 
ot 10 mglXg did not produce per ae inhibition ot brain enzyme 
even when administered into the "upper animal" where it escape. 
inactIvation by the liver. Thua it cannot be concluded on the 
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bali. ot thl1 experim.nt that potentiation of inhibition cannot 
aria. trom thi. particular admini.tration •• quence) that this 
actually can be the ca... appear. trom the Icrutiny ot the 
tollowing .xp.rim.ntl. 
When Malathion. 50 mg/Rs. was giv.n prior to EPN, 10 
mg/Kg, death occurred within halt hour and brain CnE inhibition 
reached 80 and 100 p.roent lev.ll In the medulla and cortex 
re.pecti.ely. Actually only 80 percent inhibition ot the corti-
cal enzyme could b •• xpected on the ba.il ot additi.e etteeta ot 
Malathion and ot ltPN. Similarly wheb Malathion, 60 .g,lKg, W8.8 
given $0 to 120 minute. prior to BPN, ) mg/Kg, death occurred 
within 60 minute. and again .ome potentiation ot CbE inhibition 
occurred amounting to an a.erage ot 2) to )0 perc.nt increa.e in 
inhibition above the l.v.l. .xpected on the baai. ot addit1ve 
ettectl. Those re.ult. are in agr .... nt with data obtalned in 
this laboratory indicating that potentiation ot toxicity and ot 
neuroettector action d.velops on actmlni.t.ring Malatbion prior 
to EPN in non-an •• th.tlzed dog.~ In the case ot the N.M.J. 
potentiation ot the mUlcle re.ponse to indirect stimulation 
developed in ane.thetized cat. when sUbettecti.e doae. ot Mala-
thion were given 50 minute. prior to aubett.otive do •• s ot EPN 
(Karozmar, Awad and Blachut, unpublished). 
Ther. was a relatively good corr.lation between 
toxicity &nct brain OnE inhibition when subeftective dose. ot EPN 
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was administered prior to subetteotive doses ot Malathion. On 
reversing thls .equenoe ot administration potentiation ot the 
enzrme wal not .s high In the medulla and did not exoeed 70 per-
cent In either cortex or medulla, at the tl.e ot occurrence ot 
death. In this ease other non-choline.teraaic taotors and / or 
peripheral cholinesterasio tactors could have contributed to the 
toxicity_ Thus, when EPN is administered prior to Malathion 
toxicity appears to be mainly due to potentiation ot central 
enzymio inhibition, although partioularly in the oas. ot high 
oontent ot Malathion in the combInation peripheral tactors may 
have oontributed. When on the other hand Malathion waa admini-
stered tirst, toxicity may be due to oentral potentiative ettect 
and also to potentiation at peripheral site8. This oan be sup-
ported by the tact that in oombination there Wal alwa78 complete 
inhibition ot blood CbE (a peripheral 8ite) while thia was not 
the oase with brain CbE. We may assume in thia oontext that 
Malathion oonoentrates and oontributes to potentiation preteren-
tially at peripheral 8it.s. Ceratin pharmaoological data support 
thia suggestion (lArc .. ar, Avad and Blachut, unpublished). 
Hewever, aa Indicated above, direct neuronal toxicity ot combl-
nation may al.o exi.t. 
IV. Meohanism ot potentiation: 
1. pi8orlbtion ot Cookts postulate {Malathionase slstem and 
its inhibition bl EPB~: 
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In 1957 Frawley showed that oombined administration ot 
EPK and Malathion produced potentiation ot ebE inh1bition ot RBC 
as well as potentiation at toxioity ifi rat.. Accordingly, Cook 
(19) hypothesized that the potentiation occurs due to the inhibi-
tion by one oompound ot detoxitication ot the other. ae showed 
that in vitro Malathion ia metabolized and inactivated very 
rapidly by liver homogenate. Cook et ale (19) showed also that 
detoxitication wal due to hydrolysis ot one at the succinate e.te 
groups ot Malathion. The,. a.sumad theretore that the enzyme is 
an eaterue and called it "Malathion .. s.". None ot man,. other 
organophosphorul compounds such as EPN, Ohlorthion, Guthion, 
Parathion etc. was markedly altered by the liver. Cook et ale 
(18, 19) ahowed also that phosphonate compound. auch as EPN have 
'igniticant inhibitory ettect on the degradation ot Malathion 
when added to the liver homogenate either simultaneoully with or 
prior to the addition ot Malathion. This was confirmed by 
MUl'phy and Dubois (65) who sbowed tnat So percent ot rat 11ver 
detoxifioation of the enzrme "Malathiona •• ", occurred with a 
concentration ot 2.8 ~ 10-5 M ot EPN in vitro. When. 1.5 ms/Kg 
was administered to rats 1 nour prior to Malatnion. thia dos.,of 
EPN brought about a reduction in the LD50 ot Malathion trom 1100 
to 550 mg/Kg.(l) 
2. Cook's gypoth.sls and the pre.ent results: 
The results ot the present studt partially support and 
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(1) There is no evldence to prove that "Malathionase". the 
liver enzJMe delcribed by Cook is not a cholinelterase. Cook 
et ale argued aa tollows In tavor ot .pecific "Malathion ... ". 
a. TO. very rapid alteration in vitro ot Malathion by the 
liver ditterl trom that shown tor organophosphate pe.ticide. 
generally_ When cholinesterase and some aliesterasea hydrolyse 
the.e phosphat. e.ters, the enzJNea are in turn inactivated 
or inhibited so,that one mole ot enzyme hydrolyzes only one 
mole ot phosphate betore it become. inactive. 
b. On the other hand, in the cas. ot enzymes such as DFPaae 
and Tabunase one mole ot en.,.. hydrolyses a large number ot 
moles ot the susceptible phosphate wIthout the enzyme being 
inhibited during the procesi. 
Cook Itated that "Malathionase" action doe. not appear t( 
resemble the activity ot either ot these two enzyme.. It i. 
however not clear how does Cook know that "Malathionase" i8 not 
de.troyed while hydrolysing Malathioh and thus ditters trom the 
ali •• tarales, in tact, there was no quantitative study showing 
how many mol.1 ot Malathion are hydrolyzed by one mole ot the 
enzyme. Neither is it proven that ~alathionale" behave. unlike 
DFPaa •• 
c. The enzyme attackl Malathion at the di.thyl succinate 
8ubltituent pather than at a P:S or P=O linkage aa i. do •• by 
cholineltera •• , DFPase, and Tabunase. Howevel' it is not known 
whether or not cnolinest.ra •• cannot attack tbi8 very linkage. 
Thua, it ma, be more in keeping with available data to state 
at pre.ent that the liver enzyme capable of de.troying Malatbion 
may be a cholinest.r.... In tact Cook s'Sgest.d that tho.e 
pho.phonate compounds which inhibited ~alathioDa •• • beoom. 
more potent upon oxidation Which however increased also their 
anticholinesterase actiona. Similar ettect ot oxidation on 
the.e two antlenzymic activitie. or the organophosphorus 
compound. lugS .. ts that we deal here actually with one aotivity 
only, namely that ot a cbolineateraae. It is further po •• ible 
that Malathion react. with and 1s hydrolyz.d by, this .nzyme 
thul producing a reverlible type ot interaction, while EPN al 
well aa otber organophosphorus oompounds react with but are not 
hydrolysed by, thi. enzyme thus producing an irreversible type 
ot tnteraction. 
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partially contradict Cook's h1Poth.sis. 
a. Facts sURPortins Cook's hypothesisl 
i. Liver metabolism and Malathion. The present 
study has shown that Malathion in vitro is a tairly potent anti-
choline.t.ras8 ag.nt. When incubated with liver homog.nate ita 
activity d.crea.... A do •• ot Malathion which does not inhibit 
brain CbE when given I.V. produc.s about 14 p.rc.nt inhibition 
when given intrajugularly to the "upper animal". Incubated 
Malathion produce. le •• inhibition In the ·upper animal" than the 
non-incubated compound. Thua, a1ao In vivo Malathion i. metabo-
lized, probably in the liver, to a 1 ••• activ. compound. Thia 
agre •• with Cook'. data indicating that a liver .steras. detoxi-
tie. Malathion. 
ii. Ettect. ot non-incubated compound. in vitro. 
Combined treat.mnt ot brain homog.nate in vitro by non-incubated 
EPN and Malathion cau.e. no potentiation but additive CbE inhibi-
tion. Thi. again agrees with Cook" postulate .ince 1t in.ioat •• 
that in order tor potentiation to occur !PH hal to protect 
Malathion trom de.truction. 
iif. Bttecta ot non-incubated compound. in vivo. 
Combined administration to the ·upper animal" ot non-incubated 
EPN and Malathion given intrajugu1arly and 1ntraventricularly did 
not produce potentiation ot brain ObE inhibition at 30 minutes 
atter the admini.tration ot the .econd compound (Malathion) which 
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i8 the time at which combination o~ the incubated compounds 
produced potentiation. Thi. Is an In vivo con~ir.ation o~ Cook's 
suggestion that metabollsm Is necessary In order tor potentiation 
to develop. 
iv. Ettects ot changing the sequence ot admini~tratio 
When EPN va. administered I.V. prior to Malathion in normal 
anesthetized anual potentiation or inhibition or brai.n CbE vas 
produced by inerrective doses of both compounds. The reversal 
ot the sequence ot adm1ni.tration lessened the action. This 
agree. with Cook's po.tulate that EP-N by being administered 
prior to Malathion can protect the latter trom detoxifioation by 
the liver enzyme, thus cau8ing potentiation o~ Malathion action. 
b. 'act. vhich do not 8upport Cook's hypoth.sisl 
i. Pote.tiation by inoubated compounds. In vitro 
combination ot liver-incubated EPI and Malathion produced 
potentiation of the inhibition of brain CbE. Also in vivo, 
administration to the ·upper animal" ot the liver-incubated 
combination ot EPN and Malathion produced potentiation ot brain 
CbE inhibition. It m1ght appear at tirst glance that this 
tavors Cook'. statement since potentiation ocourred only 1n the 
pre.en.e ot liver and since EPN could prevent in these conditions 
destruotion ot Malathion. However this is not the necessary 
o .. e becau •• : 
A. The concentration ot EPN added was selected 
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10 (ct. also p. 33) that EPN inhibited liver enzrme on17 and 
was not available to protect any further detoxitication of 
Malathion. 
B. In the ease ot non-incubated EPN and Malathi-
on administered 1ntrajugularly to the "upper animal" potentiation 
ot inhibition of brain ObE did not occur at 30 minutes at~er 
administration ot the second compound (Malathion) aa already 
atated. However, at 60 m1nutes potentiation did appear, particu-
larly in the cortex. Apparently then potentiation can occur in 
conditions in which Malathion oanno~ be metabolized~hus,the 
protection by EPN i. not the only factor involved. 
C. Finally incubated EPN given intraventricu-
larly potentiates ChE inhibition by non-incubated Malathion. 
In this cas. again conditions tor Malathion de.truction are not 
preaent. 
ii. Further anallsis of the ettect of changing the 
sequence ot administration. When Malathion is given 40 or even 
120 minutes prior to EPN potentiation of brain Obe inhibit10n 
and toxicity did arise in the cas. of min1mal eftective dose. of 
these two compounds. Thus BPN .ee.s to potentiate Malathion 
even when given atter 1t, thus not being in posit1on to protect 
Malathion from destruction. It should be atated her. that Cook's 
postulate becomes a working hypothe.is only it we analogize 
Malathion to A.h; 1n other words it we assume that Malathion i8 
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juat about a8 rapidly metabolized aa Ach. In thi. caa. it could 
be ea8ily vi.ulaized how aimultaneous administration of EPN and 
Malathion or particularly pretreatment with EPN may lead to 
potentiation ot the eftects ot Malathion. To the contrary even 
it 60 minute. atter administration of Malathion a certain amount 
ot it remaina intact and is protected by EPN trom further destruc-
tion it i. hard to visualize how this protection should render 
Malathion effective at that time. 
ili. Finally two more taots not reported in this work 
but available from other investigations aeem to oontradiot Oook's 
hypothesis I 
A. Rosenberg hal shown that Ohlorthion and 
Malathion are both hydrolyzed by the liver and that Ohlorthion i. 
potentiated by EPN and also potentiates Malathion. On the other 
hand Oook (18) has reported that Chlorthion is not hydrolyzed by 
the liver and that both !PN and Ohlorthion inhibit Malathion 
detoxitication by the liver. It this is true then Chlorthion 
potentiation by EPN cannot be explained according to Oook's 
hypoth.ala. On the other hand, It we accept that Ohlorthlon 1. 
hydrolyzed by the llver it la dlfficult to visualize how it can 
potentiate Malathion by the mechaniSM suggested by Oook. 
B. Potentiation cannot always depend on the 
interferenoe ot one compound with the detoxification of the other 
,inee similar potentiation was reported in the ca.e of combinatio) 
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ot neostigmine and oxamide bis-quaternaries (55). Those compounds 
are not hydrolyzed by the liver. 
3. New postulat,: 
Since several taets seem to argue against Cook's hypo-
thesis and since particularly the question raised in o.ii (p. 111) 
seems to exclude EPN protection ot Malathion as a major mechrulism 
tor potentiation, another postulate is proposed. 
a. The basil tor the new hypothesi.: 
Some in vitro as well as in vivo results indicate 
that Malathion when given after, prio~ to or simultaneously with 
EPN can prevent full effect ot the latter to be exerted. This 
oould be due to Malathion reacting taster with the enzyme than 
EPN. It may be that once Malathion combines with the enzyme it 
blocks EPN trom the site or interaction with the enzyme. It the 
enzyme has only one cationic site (which can be phosphorylated) 
Malathion could compete tor it with EPN. This does not .eem to 
be the ease since less than additive inhibition occurs even when 
Malathinn produces only partial inhibition thus assumedly per-
mitting EPN to exert additional inhibition. A slmil~ ditticulty 
in explaining interterence by one OnE inhibitor with the aotion 
or another waS reoorded in the past. Koppanyi and Karozmar (54) 
have shown that small doses ot physostigmine presumably caps.ble 
ot limited inhibition of ChE prevented pharmacological actions 
or DFP. While it oan be readily understood (Koelle, 51) how 
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~.latlv.17 large dose. or pbJa.atlgmtne can p~.t.ct CbB from DrP 
by ra •• r81blJ binding tn. ena,.., It oannot b. ..8117 .een why 
CbE inhibited .81 bJ 10 p.rQant only, should not be tully Inhibi-
ted by .ultable dose. ot DFP. 
On tbe othel' hand, bota potentiation and Mutual 
competition oould ba expected it phoapbonate and .elat., oompound. 
could act upon tbe en.,... 11'1 two dlft.rent v.,... Actually EPN 
aa' Malatbion 40 not re.et 14entlc.l1y wltb ObE tbougn tb., both 
a ••• to be 1.r ..... lbl. inblbltoft_ It i •• ugs .. ted &000"11'1811 
that CbE haa 110 •• tban one oa'lonlc ·.It. ot actlon with r.S81"d 
to ErN and Mal.thlon_ Thl. poatulate could explain alao blockade 
1.0 oer-taln coa41tl0 •• of EPN b,. Malathion, .11'10. on •• 1te could 
be attaoked bJ MalatbloG wbil. the othe. could be attack.d bJ 
EPN and blooked bJ MalatbioD. Tbl. postUlate of .ultlpl. eat Ionic 
81te. on ebE mole.ule ... ot 41ttePeatla1 60,1.1t10. JIl attiDl-
'1.. ot '9'&1"1... utlobolu .. tv.... at th... .1 t.. • • ., obvlat. 
the dlttlcultl 1n upl.a1nlng botb potentlatlon aDa tn, .. t .... . 
pnen_ena oocur1'1Dg w1th ._blnatloDa of antiebol1D .. t .... as." 
The p •• 1;u1at. 1. strengthened bJ tbe taO't ,bat aD'loholin •• t ..... 
action. of EPlf &Del Kalatb.1on 41tt .. in •• v.~al ••• p.e' •• 8lD •• 
thi. aga1D Gan be explained lt CnE mol.cule hael .... than on. 
oatlonic .1t.& 
1. Hal.tb.1cm cannot p~oduc. 100 pvcen' lnb.1bl tlon 
ot bpa1D ebE wbll. EPN .an. 
IlS 
li. In vlvo Inhlbition by EPN is greater at medullary 
than at oortlcal levela. The opposlte is true in the case ot 
Malathlon. 
111. EPN inhlbits RBO AcOnE more than it Inhiblt. 
plasma ObE, again the opposlte ls true in the case ot Malathion. 
lv. Brain ObE inhibltion by EPN oorr.lates with the 
toxiolty produced while Malathion s.ems to exhibIt elther 
perlpheral or non-cholinesteraslc components ot toxic1ty. 
v. An Important ditterence ls that EPN was shown to 
have a dual ette.t and can depending on the dOs" activate or 
Inaotlvat. brain ObE. 
b. Speoulatlve !!planation ot potegtla'ion on tq. basis 
ot the new po,tulat.t 
i. Two typ.. ot EPN-ChE interactlon •• 
BPI is .etabolized preaumably in the liver in 
two .tepa, fir.t to • oompound whioh incre •••• the activity ot 
brain ObE. Thi. can oCO\U" elther with regard to the Dumber ot 
tree or aotive .nzJBle or with regard to the number ot active site 
on the enzymio molecule. The tormer may take plaoe by competing 
with endogenous anticholine.terases (49), the latter may take 
place by exposing active site8 on the ensJae surtace which are 
normally hidden. 
Second atep ot EPN metabolism brings about anoth. 
compound which haa anticholinesteraae aotivity. 
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ii. Potentiation would then pesult when Malathion 
having acoe •• to more active site. of the enzyme atter the ettect 
ot EPN took place, would inhibit ObE more etticiently. Given 
alone, it would have difficulty getting to all lite., whioh i. 
evidenced by the tact that Malathion i. unable to produce 100 
percent inhibition ot brain ObE. In tact, the actual inhibition 
b,. EPN given .ingly may be greater than the apparent one .inee 
the brain sample trom an EPN-tpeated animals i. compared to a 
contpol sample the OnE ot which 18 not activated by EPN • 
. , 
111. Occurpance ot toxicity. It 18 .. sumed that the 
bound enzyme 1. in eqallibpium with the tunctional enzJme and 
act. as .torage trom which the latter can be peplenilhed. In 
combination, EPN and Malathion will tre. and expo •• the bouad 
enzyme and inhibit it when it 18 in the unbound torm, thua, 
nothing ot the stored enzyme would be lett available to replace 
the functional enzyme when it gets inactivat,.;d. When both the 
atored and the functional enzymes are inhlblted, Ach would 
accumulate and produces death, pre.umably via central eftecta 
such as convulsion and respiratory failure. 
iv. Occurrence of toxicity atter the ohange ot 
sequenoe of administration. When Malathion i8 given prior to 
EPN, some of it geta attaohed to the brain enzyme and at the 
periphery. This traction ot Malathion is unable to inhibit 
until EPN activates the enzyme. At that time potentiation of 
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inhibition ot ChE would be a result of more etficient ettect ot 
EPN and Malathion. In this particular sequence or adminis~ration 
toxicity occurs rather slowly, while Malathion can exert ita 
action immediately, EPN metaboliaM and activation takes time, and 
the enzymic and pharmacologic etrect is thus delayed. On the 
other hand, when the administration aequence is reversed, Mala-
thion ia administered at the time ot activation ot OhE by EPH, 
in this ease toxicity ocours taster than in the tormer. All this 
doea not neoessarily imply that proteotion ot Malathion by EPH 
trom the liver detoxifying enzyme ii not one of the mechanism 
contributing to potentiation; in taot it is telt that the 
.echaniam postulated by Cook as well aa that sugge.ted at present 
mal be both operative. Finally, peripheral oholinesterasio as 
well as peripheral and oentral non-oholinesteraa1c tactors oannot 
be excluded at present. 
CHAPTER V 
I. P9£Poae ot thia atudl' 
In 1957 Frawley et ale have ahown that combined adminis-
tration ot organophosphorus compounds, EPN and Malathion, 
produced potentiation ot toxicity and ot inhibition ot RBC CbE 
in rats. Cook et ale (19) postulated that potentiation is due 
to 1nhibition ot detoxltication ot one compound by the other • 
. , 
They demonstrated that in vitro Malathion 1s de.troyed by the 
liver and that EPN protects Malathion trom this destruction. 
'1'hls waa contirmed by data ot Murphy and Dubois (6$). suggesting 
that EPN inhibit. irreversibly the liver "Malathionaae". 
Since death could not be attributed to inhibition ot CbE 
ot RBCs and ainee no studies were carried out with regard to the 
ettect ot organophosphorus combinations upon the brain enzyme, 
detailed biochemical investigations ot brain CbE and ot its 
interaction with EPN and Malathion and with their combinations 
were undertaken. Suitable daba were also collected tor re.x .. i-
nation ot Cookla postulate. 
II. Progeaur!!1 
1. Ane.thetized dogs as well aa Ruppel" animal" preparations 
were u.ed in the present study. In the ca.e ot the latter the 
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agents could be .'ministe~ed so that they would not circulate in 
the liver or any other visceral organs. Both liver-incubated 
and non-inoubated oompounds were adminlatered to the ·upper 
animal" ao that the ettect ot metabolism on the oompounds in 
question could be studied in vivo in abs.nce ot the animal'a own 
"Malath.ionase". 
2. Intraventricular administration ot inoubated and ot non-
incubated compounds was used to study the role of their meta-
bolism as well as of the blood-brain barrier in action of th.e 
compounds and ot their combinations.: 
3. A systematic study of EPN and of Malathion actions on 
brain CbB was carried out in vl'ro as well a8 in vivo. In vivo, 
dltterent parts ot brain tissue were analysed tor their CbE 
activity. 
4. Warbupg manometrlc technique was used exolusively tor 
measupementof AcOnE and BuChE actlvitl.s. 
s. Interaction ot EPN and ot Malathion with CbE was studied 
using dialya18 and dilution techniques. The compounda inh1bit 
the enzyme irreversibly; also, no tree compounds could be de· 
monstrated in tiasue samples trom animals treated in vivo • 
Thus, no tree compound could be released during homogenization 
and additionally inhibit the enzyme. 
6. Irreveraibility ot inhibition and abaence ot tree 
oompounds atter their adminiatration indioat. reliabtltt, ot 
ot measurement. of ebE inhibition. 
III. aesult.: 
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1. EPN vas found to be a weak ebB inhibltor in vitro. but 
rather potent inhlbltor in vivo. It has to be metabolized by the 
liver to become an etteetive antieholinestera.e. 
2. In vivo, EPN inhibited medullary enzyme more than eorti-
oal one. 
3. At toxio do.e ot EPN inhibited nearly 100 percent of 
brain CbE activity. 
4. Malathion vas found to b. t.~rly active ant1cholinesteras 
in vitro, in vivo It was weak inhibitor due to the taot that it 
i. destroyed by liver enzrme. 
S. Malathion Inhibited cortical more tban •• 4ull&rJ enaya •• 
At toxic dose It inhibited maximally only 70 percent ot brain 
CbE) this .uggest. peripheral or non-cholinesterasi. oomponents 
ot to%101t1. 
6. EPN was tound to have a dual ettect, 1n amall do.e. it 
inore .. ed brain CbB actlvitYJ large d08es oaused inhlbltion, on 
the other hand Malathion did not Incr ••• e the enzyme activity at 
any do.e atudied. 
7. EPN and Malathion Inhiblted in vivo brain p •• udo ebE 
aimilarly to the true CbE. 
8. Potentiation of enzymic Inhibition in vitro occurred 
on11 from the eombination ot liver-incubated compound •• 
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9. Potentiation ot brain abE inhibition in vivo occurred 
when EPN was given prior te Malathion. When Malathion was given 
prior to EPN, potentiation ocourred in the case ot certain doses 
but it was less extensive than in the case ot the former sequence 
10. With both sequences ot administration death occurred. 
The extent ot ObE inhibition ot ditterent parts ot the brain and 
the speed with which toxicity occurred depended on the ratio ot 
the two compounds in the combination. 
11. In the "upper animal" rapid and extensive potentiation 
ot brain ObE inhibition occurred trom combination ot EPN and 
Malathion when both compounds or EPN alone were incubated with 
liver homogenate. Some potentiation occurred however even in 
the ca.e ot non-incubated compounds atter a prolonged delay. 
12. In the case ot intraventricular administration poten-
tiation occurred upon administration ot liver-incubated compounds. 
13. Analysis and comparilon ot data obtained upon admini-
stration ot EPN and Malathion and their combinations intra-
jugularly and intraventricularly in the "upper animal" or I.V. in 
the whole animal .ugge.t that liver incubation ot EPN activate. 
the compound but is not necessary to enable it to cross the 
blood-brain barrier; liver incubation ot Malathion inactivates it 
but again does not attect its capacity to penetrate the blood-
brain barrier. 
IV. AnalIsis ot Cook's postUlate. 
l~ 
Some ot the re.ult. obtained support Cook's hypothe.iaJ 
some other do not. 
1. Potentiation ot toxioity and brain CnE inhibition 
oocurs not only by administering EPN prior to Malathion but also 
when this sequence is reversed. Aocording to Cook's postulate 
when EPN is admini.tered atter Malathion little or no Malathion 
1. lett in the cas. ot Malathion-EPN aequence by the time ot EPN 
administration and the protection ot Malathion re.idue by EPN 
oould not result in potentiation. 
., 
2. Potentiation oocur. when incubated BPN i. adminis-
tered with Malathion intraventricularly or intrajugularly in the 
"upper animal". It is shown that EPN in the.e condition. does 
not protect Malathion trom hydroly.is in it. inoubation medium. 
3. Other data as well as certain result. ot other 
investigators also do not agree with Cook's po.tulate. 
4. A new postulate is based on the suggestion that 
provided EPN and Malathion do not react identically upon ChE, 
the potentiation may result trom their interaotion with the 
enzyme and does not have to depend on the proteotion afforded 
one oompound from destruction by the other. Some ot the 
difterenoes between ettect. ot EPN and Malathion are as tollows: 
a. EPN but not Malathion has a dual action upon ChE. 
b. EPN inhibits preterentially RBC and Malathion 
plasma CnE 
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c. EPN inhibits more medullary than cortical ChE; 
the opposite is true for Malathion. 
d. EPN but not Malathion can produce 100 percent 
inhibition of brain ChE at death. 
5. The new postulate suggests that. 
a. EPN is metabolized in two steps. Metabolite 1 
activates CnE; Metabolite 2 inhibits it. 
b. Activated ChE i8 more liable to inhibition than 
control ChE. 
c. Malathion attaches itself to CbE but cannot 
inhibit it efficiently until the aetivating action ot EPN takes 
place, henee potentiation. 
d. Certain o~her aspects ot the new postulate and 
their relation to data available in literature are analyzed 
turther in the discussion. 
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